US20210162173A1 - Fluid delivery systems and methods - Google Patents
Fluid delivery systems and methods Download PDFInfo
- Publication number
- US20210162173A1 US20210162173A1 US17/172,817 US202117172817A US2021162173A1 US 20210162173 A1 US20210162173 A1 US 20210162173A1 US 202117172817 A US202117172817 A US 202117172817A US 2021162173 A1 US2021162173 A1 US 2021162173A1
- Authority
- US
- United States
- Prior art keywords
- catheter
- port
- septum
- various embodiments
- accordance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012530 fluid Substances 0.000 title claims abstract description 86
- 238000000034 method Methods 0.000 title abstract description 19
- 238000007913 intrathecal administration Methods 0.000 claims abstract description 61
- 238000007920 subcutaneous administration Methods 0.000 claims description 13
- 210000003195 fascia Anatomy 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 206010008164 Cerebrospinal fluid leakage Diseases 0.000 abstract description 8
- 239000003814 drug Substances 0.000 description 38
- 210000001519 tissue Anatomy 0.000 description 27
- 229940124597 therapeutic agent Drugs 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 239000013078 crystal Substances 0.000 description 14
- 241001269524 Dura Species 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 12
- 210000003169 central nervous system Anatomy 0.000 description 11
- 238000002513 implantation Methods 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 230000006835 compression Effects 0.000 description 9
- 238000007906 compression Methods 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 229910052751 metal Inorganic materials 0.000 description 9
- 239000002184 metal Substances 0.000 description 9
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 8
- 108010025020 Nerve Growth Factor Proteins 0.000 description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 230000002787 reinforcement Effects 0.000 description 8
- 239000013607 AAV vector Substances 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 230000000007 visual effect Effects 0.000 description 7
- 230000004323 axial length Effects 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- -1 polytetrafluoroethylene Polymers 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- 201000011240 Frontotemporal dementia Diseases 0.000 description 5
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 5
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 5
- 102000015336 Nerve Growth Factor Human genes 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 229940053128 nerve growth factor Drugs 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 208000002320 spinal muscular atrophy Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 4
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 4
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 4
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 4
- 241000702421 Dependoparvovirus Species 0.000 description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 4
- 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 208000009575 Angelman syndrome Diseases 0.000 description 3
- 201000007547 Dravet syndrome Diseases 0.000 description 3
- 101001112229 Homo sapiens Neutrophil cytosol factor 1 Proteins 0.000 description 3
- 101001112224 Homo sapiens Neutrophil cytosol factor 2 Proteins 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 3
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 3
- 102000007072 Nerve Growth Factors Human genes 0.000 description 3
- 102100023620 Neutrophil cytosol factor 1 Human genes 0.000 description 3
- 102100023618 Neutrophil cytosol factor 2 Human genes 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 239000004696 Poly ether ether ketone Substances 0.000 description 3
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 description 3
- 206010058907 Spinal deformity Diseases 0.000 description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000000712 assembly Effects 0.000 description 3
- 238000000429 assembly Methods 0.000 description 3
- 229940090047 auto-injector Drugs 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000005684 electric field Effects 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 108010072166 idursulfase Proteins 0.000 description 3
- 238000009593 lumbar puncture Methods 0.000 description 3
- 210000002161 motor neuron Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229920002530 polyetherether ketone Polymers 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 108010026424 tau Proteins Proteins 0.000 description 3
- 102000013498 tau Proteins Human genes 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical group COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000018282 ACys amyloidosis Diseases 0.000 description 2
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 2
- 101710151768 Aromatic-L-amino-acid decarboxylase Proteins 0.000 description 2
- 238000010453 CRISPR/Cas method Methods 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 2
- 108010083068 Dual Oxidases Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 description 2
- 208000024412 Friedreich ataxia Diseases 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 108020005004 Guide RNA Proteins 0.000 description 2
- 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 description 2
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 description 2
- 102000004627 Iduronidase Human genes 0.000 description 2
- 108010003381 Iduronidase Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 2
- 108010082739 NADPH Oxidase 2 Proteins 0.000 description 2
- 102000004230 Neurotrophin 3 Human genes 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- 102100033857 Neurotrophin-4 Human genes 0.000 description 2
- 108090000095 Neurotrophin-6 Proteins 0.000 description 2
- 102100021584 Neurturin Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229960002396 idursulfase Drugs 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 1
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 1
- WWFDJIVIDXJAQR-FFWSQMGZSA-N 1-[(2R,3R,4R,5R)-4-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-sulfanylphosphoryl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound COCCO[C@@H]1[C@H](O)[C@@H](COP(O)(=S)O[C@@H]2[C@@H](COP(S)(=O)O[C@@H]3[C@@H](COP(O)(=S)O[C@@H]4[C@@H](COP(O)(=S)O[C@@H]5[C@@H](COP(O)(=S)O[C@@H]6[C@@H](COP(O)(=S)O[C@@H]7[C@@H](COP(O)(=S)O[C@@H]8[C@@H](COP(O)(=S)O[C@@H]9[C@@H](COP(O)(=S)O[C@@H]%10[C@@H](COP(O)(=S)O[C@@H]%11[C@@H](COP(O)(=S)O[C@@H]%12[C@@H](COP(O)(=S)O[C@@H]%13[C@@H](COP(O)(=S)O[C@@H]%14[C@@H](COP(O)(=S)O[C@@H]%15[C@@H](COP(O)(=S)O[C@@H]%16[C@@H](COP(O)(=S)O[C@@H]%17[C@@H](COP(O)(=S)O[C@@H]%18[C@@H](CO)O[C@H]([C@@H]%18OCCOC)n%18cc(C)c(=O)[nH]c%18=O)O[C@H]([C@@H]%17OCCOC)n%17cc(C)c(N)nc%17=O)O[C@H]([C@@H]%16OCCOC)n%16cnc%17c(N)ncnc%16%17)O[C@H]([C@@H]%15OCCOC)n%15cc(C)c(N)nc%15=O)O[C@H]([C@@H]%14OCCOC)n%14cc(C)c(=O)[nH]c%14=O)O[C@H]([C@@H]%13OCCOC)n%13cc(C)c(=O)[nH]c%13=O)O[C@H]([C@@H]%12OCCOC)n%12cc(C)c(=O)[nH]c%12=O)O[C@H]([C@@H]%11OCCOC)n%11cc(C)c(N)nc%11=O)O[C@H]([C@@H]%10OCCOC)n%10cnc%11c(N)ncnc%10%11)O[C@H]([C@@H]9OCCOC)n9cc(C)c(=O)[nH]c9=O)O[C@H]([C@@H]8OCCOC)n8cnc9c(N)ncnc89)O[C@H]([C@@H]7OCCOC)n7cnc8c(N)ncnc78)O[C@H]([C@@H]6OCCOC)n6cc(C)c(=O)[nH]c6=O)O[C@H]([C@@H]5OCCOC)n5cnc6c5nc(N)[nH]c6=O)O[C@H]([C@@H]4OCCOC)n4cc(C)c(N)nc4=O)O[C@H]([C@@H]3OCCOC)n3cc(C)c(=O)[nH]c3=O)O[C@H]([C@@H]2OCCOC)n2cnc3c2nc(N)[nH]c3=O)O[C@H]1n1cnc2c1nc(N)[nH]c2=O WWFDJIVIDXJAQR-FFWSQMGZSA-N 0.000 description 1
- DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 102100024049 A-kinase anchor protein 13 Human genes 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102000017920 ADRB1 Human genes 0.000 description 1
- 102100029592 Activator of apoptosis harakiri Human genes 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 102100031260 Acyl-coenzyme A thioesterase THEM4 Human genes 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 241000649045 Adeno-associated virus 10 Species 0.000 description 1
- 241000649046 Adeno-associated virus 11 Species 0.000 description 1
- 102100034561 Alpha-N-acetylglucosaminidase Human genes 0.000 description 1
- 102100026882 Alpha-synuclein Human genes 0.000 description 1
- 102100034452 Alternative prion protein Human genes 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101000798762 Anguilla anguilla Troponin C, skeletal muscle Proteins 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 102100021987 Apoptosis-stimulating of p53 protein 1 Human genes 0.000 description 1
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 1
- 102100031491 Arylsulfatase B Human genes 0.000 description 1
- 102000007372 Ataxin-1 Human genes 0.000 description 1
- 108010032963 Ataxin-1 Proteins 0.000 description 1
- 108010032947 Ataxin-3 Proteins 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 102000007368 Ataxin-7 Human genes 0.000 description 1
- 108010032953 Ataxin-7 Proteins 0.000 description 1
- 102100035656 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Human genes 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical group OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 102100021251 Beclin-1 Human genes 0.000 description 1
- 102100021257 Beta-secretase 1 Human genes 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 1
- 102100032312 Brevican core protein Human genes 0.000 description 1
- 101150060120 C1qbp gene Proteins 0.000 description 1
- SPEZAIOWFCKIQT-POUAJXSMSA-N CC(C)OC[C@]12O[C@@H](C)[C@H](O[C@H]1C)[C@@H]2OP(C)(=O)OC(C)C Chemical compound CC(C)OC[C@]12O[C@@H](C)[C@H](O[C@H]1C)[C@@H]2OP(C)(=O)OC(C)C SPEZAIOWFCKIQT-POUAJXSMSA-N 0.000 description 1
- 102100031168 CCN family member 2 Human genes 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 102100033093 Calcium/calmodulin-dependent protein kinase type II subunit alpha Human genes 0.000 description 1
- 102100029398 Calpain small subunit 1 Human genes 0.000 description 1
- 102100025172 Calpain-1 catalytic subunit Human genes 0.000 description 1
- 208000022526 Canavan disease Diseases 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 102100032616 Caspase-2 Human genes 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102100032219 Cathepsin D Human genes 0.000 description 1
- 102100035244 Cerebellin-1 Human genes 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000004360 Cofilin 1 Human genes 0.000 description 1
- 108090000996 Cofilin 1 Proteins 0.000 description 1
- 102100037078 Complement component 1 Q subcomponent-binding protein, mitochondrial Human genes 0.000 description 1
- 102100026865 Cyclin-dependent kinase 5 activator 1 Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102100025620 Cytochrome b-245 light chain Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102100026139 DNA damage-inducible transcript 4 protein Human genes 0.000 description 1
- 102100025900 DNA damage-inducible transcript 4-like protein Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 101100457345 Danio rerio mapk14a gene Proteins 0.000 description 1
- 101100457347 Danio rerio mapk14b gene Proteins 0.000 description 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 1
- 102000006265 Dual Oxidases Human genes 0.000 description 1
- 102100021218 Dual oxidase 1 Human genes 0.000 description 1
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 description 1
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 1
- 102100022207 E3 ubiquitin-protein ligase parkin Human genes 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 101150078651 Epha4 gene Proteins 0.000 description 1
- 102100021616 Ephrin type-A receptor 4 Human genes 0.000 description 1
- 102100021606 Ephrin type-A receptor 7 Human genes 0.000 description 1
- 102100023721 Ephrin-B2 Human genes 0.000 description 1
- 102100023733 Ephrin-B3 Human genes 0.000 description 1
- 108010044085 Ephrin-B3 Proteins 0.000 description 1
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 102000003869 Frataxin Human genes 0.000 description 1
- 108090000217 Frataxin Proteins 0.000 description 1
- 102000017696 GABRA1 Human genes 0.000 description 1
- 102000000802 Galectin 3 Human genes 0.000 description 1
- 108010001517 Galectin 3 Proteins 0.000 description 1
- 102100021337 Gap junction alpha-1 protein Human genes 0.000 description 1
- 102100035184 General transcription and DNA repair factor IIH helicase subunit XPD Human genes 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 1
- 102100035902 Glutamate decarboxylase 1 Human genes 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 1
- 108700010013 HMGB1 Proteins 0.000 description 1
- 101150021904 HMGB1 gene Proteins 0.000 description 1
- 102100037907 High mobility group protein B1 Human genes 0.000 description 1
- 102100022128 High mobility group protein B2 Human genes 0.000 description 1
- 101000833679 Homo sapiens A-kinase anchor protein 13 Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000987827 Homo sapiens Activator of apoptosis harakiri Proteins 0.000 description 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 1
- 101000638510 Homo sapiens Acyl-coenzyme A thioesterase THEM4 Proteins 0.000 description 1
- 101000924727 Homo sapiens Alternative prion protein Proteins 0.000 description 1
- 101000924474 Homo sapiens Annexin A2 Proteins 0.000 description 1
- 101000752722 Homo sapiens Apoptosis-stimulating of p53 protein 1 Proteins 0.000 description 1
- 101000803294 Homo sapiens BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Proteins 0.000 description 1
- 101000894649 Homo sapiens Beclin-1 Proteins 0.000 description 1
- 101000892264 Homo sapiens Beta-1 adrenergic receptor Proteins 0.000 description 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- 101000731086 Homo sapiens Brevican core protein Proteins 0.000 description 1
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 1
- 101000944249 Homo sapiens Calcium/calmodulin-dependent protein kinase type II subunit alpha Proteins 0.000 description 1
- 101000919194 Homo sapiens Calpain small subunit 1 Proteins 0.000 description 1
- 101000934069 Homo sapiens Calpain-1 catalytic subunit Proteins 0.000 description 1
- 101000715398 Homo sapiens Caspase-1 Proteins 0.000 description 1
- 101000867612 Homo sapiens Caspase-2 Proteins 0.000 description 1
- 101000983523 Homo sapiens Caspase-9 Proteins 0.000 description 1
- 101000869010 Homo sapiens Cathepsin D Proteins 0.000 description 1
- 101000737277 Homo sapiens Cerebellin-1 Proteins 0.000 description 1
- 101000856723 Homo sapiens Cytochrome b-245 light chain Proteins 0.000 description 1
- 101100009169 Homo sapiens DDIT4L gene Proteins 0.000 description 1
- 101000912753 Homo sapiens DNA damage-inducible transcript 4 protein Proteins 0.000 description 1
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 101000898708 Homo sapiens Ephrin type-A receptor 7 Proteins 0.000 description 1
- 101001049392 Homo sapiens Ephrin-B2 Proteins 0.000 description 1
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 1
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 description 1
- 101000893331 Homo sapiens Gamma-aminobutyric acid receptor subunit alpha-1 Proteins 0.000 description 1
- 101000894966 Homo sapiens Gap junction alpha-1 protein Proteins 0.000 description 1
- 101000876511 Homo sapiens General transcription and DNA repair factor IIH helicase subunit XPD Proteins 0.000 description 1
- 101001045791 Homo sapiens High mobility group protein B2 Proteins 0.000 description 1
- 101000619663 Homo sapiens Leucine-rich repeat-containing protein 1 Proteins 0.000 description 1
- 101000573901 Homo sapiens Major prion protein Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101000880402 Homo sapiens Metalloreductase STEAP4 Proteins 0.000 description 1
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 1
- 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 1
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 1
- 101000616778 Homo sapiens Myelin-associated glycoprotein Proteins 0.000 description 1
- 101000589632 Homo sapiens N-acetylaspartate synthetase Proteins 0.000 description 1
- 101000651201 Homo sapiens N-sulphoglucosamine sulphohydrolase Proteins 0.000 description 1
- 101001108197 Homo sapiens NADPH oxidase activator 1 Proteins 0.000 description 1
- 101000603359 Homo sapiens NADPH oxidase organizer 1 Proteins 0.000 description 1
- 101000581986 Homo sapiens Neurocan core protein Proteins 0.000 description 1
- 101000973259 Homo sapiens Neurogranin Proteins 0.000 description 1
- 101001108246 Homo sapiens Neuronal pentraxin-2 Proteins 0.000 description 1
- 101000602176 Homo sapiens Neurotensin/neuromedin N Proteins 0.000 description 1
- 101001108441 Homo sapiens Neurturin Proteins 0.000 description 1
- 101000982376 Homo sapiens Oligodendrocyte-myelin glycoprotein Proteins 0.000 description 1
- 101001098175 Homo sapiens P2X purinoceptor 7 Proteins 0.000 description 1
- 101001060744 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP1A Proteins 0.000 description 1
- 101001067189 Homo sapiens Plexin-A1 Proteins 0.000 description 1
- 101001067187 Homo sapiens Plexin-A2 Proteins 0.000 description 1
- 101001067174 Homo sapiens Plexin-B1 Proteins 0.000 description 1
- 101001094872 Homo sapiens Plexin-C1 Proteins 0.000 description 1
- 101000589450 Homo sapiens Poly(ADP-ribose) glycohydrolase Proteins 0.000 description 1
- 101001135493 Homo sapiens Potassium voltage-gated channel subfamily C member 4 Proteins 0.000 description 1
- 101000974715 Homo sapiens Potassium voltage-gated channel subfamily E member 3 Proteins 0.000 description 1
- 101001099423 Homo sapiens Proenkephalin-A Proteins 0.000 description 1
- 101000611939 Homo sapiens Programmed cell death protein 2 Proteins 0.000 description 1
- 101000666171 Homo sapiens Protein-glutamine gamma-glutamyltransferase 2 Proteins 0.000 description 1
- 101000695844 Homo sapiens Receptor-type tyrosine-protein phosphatase zeta Proteins 0.000 description 1
- 101000669917 Homo sapiens Rho-associated protein kinase 1 Proteins 0.000 description 1
- 101000587820 Homo sapiens Selenide, water dikinase 1 Proteins 0.000 description 1
- 101000739905 Homo sapiens Sestrin-2 Proteins 0.000 description 1
- 101000714470 Homo sapiens Synaptotagmin-1 Proteins 0.000 description 1
- 101000891092 Homo sapiens TAR DNA-binding protein 43 Proteins 0.000 description 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 1
- 101000666340 Homo sapiens Tenascin Proteins 0.000 description 1
- 101000711846 Homo sapiens Transcription factor SOX-9 Proteins 0.000 description 1
- 101000844518 Homo sapiens Transient receptor potential cation channel subfamily M member 7 Proteins 0.000 description 1
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 description 1
- 101000801227 Homo sapiens Tumor necrosis factor receptor superfamily member 19 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 101000644689 Homo sapiens Ubiquitin-conjugating enzyme E2 K Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 101000743798 Homo sapiens Zinc finger HIT domain-containing protein 1 Proteins 0.000 description 1
- 101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 description 1
- 101001129796 Homo sapiens p53-induced death domain-containing protein 1 Proteins 0.000 description 1
- 101000743197 Homo sapiens pre-mRNA 3' end processing protein WDR33 Proteins 0.000 description 1
- 101150069138 HtrA2 gene Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108010016648 Immunophilins Proteins 0.000 description 1
- 102000000521 Immunophilins Human genes 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004034 Kelch-Like ECH-Associated Protein 1 Human genes 0.000 description 1
- 108090000484 Kelch-Like ECH-Associated Protein 1 Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 description 1
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 description 1
- 102100022237 Leucine-rich repeat-containing protein 1 Human genes 0.000 description 1
- 108700012928 MAPK14 Proteins 0.000 description 1
- 108091007877 MYCBP2 Proteins 0.000 description 1
- 101150003941 Mapk14 gene Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027236 Meningitis fungal Diseases 0.000 description 1
- 206010027260 Meningitis viral Diseases 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 102100037654 Metalloreductase STEAP4 Human genes 0.000 description 1
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 1
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 1
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 1
- 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 description 1
- 102100032380 N-acetylaspartate synthetase Human genes 0.000 description 1
- 102100027661 N-sulphoglucosamine sulphohydrolase Human genes 0.000 description 1
- 102000004019 NADPH Oxidase 1 Human genes 0.000 description 1
- 108090000424 NADPH Oxidase 1 Proteins 0.000 description 1
- 108010082699 NADPH Oxidase 4 Proteins 0.000 description 1
- 108010082695 NADPH Oxidase 5 Proteins 0.000 description 1
- 102100021872 NADPH oxidase 4 Human genes 0.000 description 1
- 102100021871 NADPH oxidase 5 Human genes 0.000 description 1
- 102100021882 NADPH oxidase activator 1 Human genes 0.000 description 1
- 102100039033 NADPH oxidase organizer 1 Human genes 0.000 description 1
- 102100021867 Natural resistance-associated macrophage protein 2 Human genes 0.000 description 1
- 102000014413 Neuregulin Human genes 0.000 description 1
- 108050003475 Neuregulin Proteins 0.000 description 1
- 102100030466 Neurocan core protein Human genes 0.000 description 1
- 102100022159 Neurogranin Human genes 0.000 description 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 1
- 102100021878 Neuronal pentraxin-2 Human genes 0.000 description 1
- 108090000772 Neuropilin-1 Proteins 0.000 description 1
- 108090000770 Neuropilin-2 Proteins 0.000 description 1
- 102100037590 Neurotensin/neuromedin N Human genes 0.000 description 1
- 102000003683 Neurotrophin-4 Human genes 0.000 description 1
- 108010015406 Neurturin Proteins 0.000 description 1
- 108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 1
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 1
- 102000000343 Nogo Receptor 1 Human genes 0.000 description 1
- 108010041199 Nogo Receptor 1 Proteins 0.000 description 1
- 102100026746 Oligodendrocyte-myelin glycoprotein Human genes 0.000 description 1
- 102100037602 P2X purinoceptor 7 Human genes 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 1
- 102100020739 Peptidyl-prolyl cis-trans isomerase FKBP4 Human genes 0.000 description 1
- 102100036660 Persephin Human genes 0.000 description 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 1
- 102100034382 Plexin-A1 Human genes 0.000 description 1
- 102100034381 Plexin-A2 Human genes 0.000 description 1
- 102100034384 Plexin-B1 Human genes 0.000 description 1
- 102100035381 Plexin-C1 Human genes 0.000 description 1
- 102100032347 Poly(ADP-ribose) glycohydrolase Human genes 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 102100033165 Potassium voltage-gated channel subfamily C member 4 Human genes 0.000 description 1
- 102100022753 Potassium voltage-gated channel subfamily E member 3 Human genes 0.000 description 1
- 102100038931 Proenkephalin-A Human genes 0.000 description 1
- 102100040676 Programmed cell death protein 2 Human genes 0.000 description 1
- 102100023068 Protein kinase C-binding protein NELL1 Human genes 0.000 description 1
- 102100034433 Protein kinase C-binding protein NELL2 Human genes 0.000 description 1
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 1
- 101150058540 RAC1 gene Proteins 0.000 description 1
- 102000003890 RNA-binding protein FUS Human genes 0.000 description 1
- 108090000292 RNA-binding protein FUS Proteins 0.000 description 1
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 1
- 102100028508 Receptor-type tyrosine-protein phosphatase zeta Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100039313 Rho-associated protein kinase 1 Human genes 0.000 description 1
- 108091006618 SLC11A2 Proteins 0.000 description 1
- 108091006264 SLC4A7 Proteins 0.000 description 1
- 102100031163 Selenide, water dikinase 1 Human genes 0.000 description 1
- 102100021117 Serine protease HTRA2, mitochondrial Human genes 0.000 description 1
- 102100037576 Sestrin-2 Human genes 0.000 description 1
- 206010040840 Skin erosion Diseases 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 102000006633 Sodium-Bicarbonate Symporters Human genes 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 102100036417 Synaptotagmin-1 Human genes 0.000 description 1
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 description 1
- 102000003615 TRPM2 Human genes 0.000 description 1
- 101150095096 TRPM2 gene Proteins 0.000 description 1
- 102000003611 TRPM7 Human genes 0.000 description 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 1
- 102100038126 Tenascin Human genes 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 102100034204 Transcription factor SOX-9 Human genes 0.000 description 1
- 108010040625 Transforming Protein 1 Src Homology 2 Domain-Containing Proteins 0.000 description 1
- 102000002015 Transforming Protein 1 Src Homology 2 Domain-Containing Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
- 102100033760 Tumor necrosis factor receptor superfamily member 19 Human genes 0.000 description 1
- 102100020696 Ubiquitin-conjugating enzyme E2 K Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 102100039044 Zinc finger HIT domain-containing protein 1 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940022705 aldurazyme Drugs 0.000 description 1
- 229960003305 alfaxalone Drugs 0.000 description 1
- 108010009380 alpha-N-acetyl-D-glucosaminidase Proteins 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960001050 bupivacaine hydrochloride Drugs 0.000 description 1
- 102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 229940052036 carbidopa / levodopa Drugs 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229960002925 clonidine hydrochloride Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 108050003126 conotoxin Proteins 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 239000003145 cytotoxic factor Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940012882 elaprase Drugs 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 229950009694 elenbecestat Drugs 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 201000010056 fungal meningitis Diseases 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 208000025014 late infantile neuronal ceroid lipofuscinosis Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- AACUJFVOHGRMTR-DPXNYUHVSA-N n-[3-[(4as,5r,7as)-2-amino-5-methyl-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-(difluoromethyl)pyrazine-2-carboxamide Chemical compound C=1C=C(F)C([C@]23CO[C@@H]([C@H]2CSC(N)=N3)C)=CC=1NC(=O)C1=CN=C(C(F)F)C=N1 AACUJFVOHGRMTR-DPXNYUHVSA-N 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 108010064131 neuronal Cdk5 activator (p25-p35) Proteins 0.000 description 1
- 208000002040 neurosyphilis Diseases 0.000 description 1
- 229940097998 neurotrophin 4 Drugs 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 229950001015 nusinersen Drugs 0.000 description 1
- 102100031691 p53-induced death domain-containing protein 1 Human genes 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 108010070453 persephin Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 102100038155 pre-mRNA 3' end processing protein WDR33 Human genes 0.000 description 1
- APGDTXUMTIZLCJ-CGVGKPPMSA-N prednisolone succinate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 APGDTXUMTIZLCJ-CGVGKPPMSA-N 0.000 description 1
- 229950004597 prednisolone succinate Drugs 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000037959 spinal tumor Diseases 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 108010067247 tacrolimus binding protein 4 Proteins 0.000 description 1
- JCQBWMAWTUBARI-UHFFFAOYSA-N tert-butyl 3-ethenylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(C=C)C1 JCQBWMAWTUBARI-UHFFFAOYSA-N 0.000 description 1
- 229960005333 tetrabenazine Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000005641 tunneling Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 201000010044 viral meningitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/0102—Insertion or introduction using an inner stiffening member, e.g. stylet or push-rod
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
- A61M25/007—Side holes, e.g. their profiles or arrangements; Provisions to keep side holes unblocked
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/02—Holding devices, e.g. on the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0208—Subcutaneous access sites for injecting or removing fluids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
- A61B5/686—Permanently implanted devices, e.g. pacemakers, other stimulators, biochips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
- A61M2025/0073—Tip designed for influencing the flow or the flow velocity of the fluid, e.g. inserts for twisted or vortex flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0208—Subcutaneous access sites for injecting or removing fluids
- A61M2039/0238—Subcutaneous access sites for injecting or removing fluids having means for locating the implanted device to insure proper injection, e.g. radio-emitter, protuberances, radio-opaque markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0464—Cerebrospinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1003—Spinal column
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M25/005—Catheters; Hollow probes characterised by structural features with embedded materials for reinforcement, e.g. wires, coils, braids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/0105—Steering means as part of the catheter or advancing means; Markers for positioning
- A61M25/0108—Steering means as part of the catheter or advancing means; Markers for positioning using radio-opaque or ultrasound markers
Definitions
- the present disclosure generally relates to fluid delivery systems and, more particularly, to intrathecal fluid delivery systems.
- Intrathecal administration is a valuable tool for introducing therapeutic agents into the cerebral spinal fluid (CSF), which allows distribution throughout the central nervous system. Indeed, therapeutics administered to CSF are distributed to the brain and spinal cord, thereby avoiding potential delivery issues through the blood-brain barrier. Most drugs delivered to the CSF require multiple administrations, requiring at least periodic access to the intrathecal space over the course of a treatment regimen. Some individuals are unable to receive medication via lumbar puncture due to anatomical barriers, such as spinal deformities, and/or surgical interventions, such as implantation of stabilizing rods and spondylosis.
- CSF cerebral spinal fluid
- Bone fusions, sharp angles, and instrumentation in these individuals complicate or prevent direct lumbar puncture entry into the intrathecal space because there is no space between the bones to allow safe puncture of the dura.
- extraordinary means are often required to achieve intrathecal access; for example, an oscillating drill may be required to bore through the bone mass or a laminectomy procedure may be required, which heightens the risk associated with intrathecal administration.
- an oscillating drill may be required to bore through the bone mass or a laminectomy procedure may be required, which heightens the risk associated with intrathecal administration.
- a fluid delivery system in accordance with one aspect, includes a port that is implantable to a subcutaneous location.
- the port includes a body that defines a chamber having an open top and a delivery opening and a septum coupled to the body to extend over the open top of the chamber.
- the fluid delivery system further includes an intrathecal catheter that has a proximal end that is configured to be coupled to the port and fluidly coupled to the delivery opening of the chamber, a distal end, a central passage extending between the proximal end and the distal end, and a distal outlet in the distal end.
- the fluid delivery system further includes a plug that has a body with a passage to receive the intrathecal catheter therethrough, where the plug is configured to be inserted into the fascia to protect against leakage of cerebrospinal fluid.
- the intrathecal catheter can include a plurality of radially oriented outlets, where the plurality of radially oriented outlets can be disposed along an axial length of the intrathecal catheter in a spiral configuration, the plurality of radially oriented outlets can include at least one of: one or more rings of outlets disposed within a plane normal to an axial length of the intrathecal catheter or a plurality of outlets aligned and spaced from one another along the axial length of the intrathecal catheter.
- the fluid delivery system can include one or more of the following aspects: the intrathecal catheter can be radiopaque; the intrathecal catheter can include radiopaque markings at one or more of: adjacent to the distal end, above a start of the plurality of radially oriented outlets, or below an end of the radially oriented outlets; at least a portion of the intrathecal catheter can have a 3 layer construction including an inner lumen, a reinforcement layer, and an outer jacket; the distal end of the intrathecal catheter can include an atraumatic tip allowing implantation without damaging or exiting the intrathecal space; the central passage can include a choked portion adjacent to the distal outlet to create a venturi effect with fluid being dispensed through the distal outlet; the distal end of the intrathecal catheter can include one or more side passages that fluidly couple the central passage to an exterior of the intrathecal catheter to draw in fluid from the exterior of the intrathecal catheter and provide flow mass amplification to fluid being dispensed through the distal outlet;
- a method of delivering an agent to a patient that has undergone a spinal stabilization or fusion procedure or suffers from a spinal deformity includes implanting a fluid delivery system in the patient such that a catheter of the fluid delivery system is disposed within the patient's intrathecal space, the catheter characterized by a catheter body having an outer diameter in the range of about 0.25 mm to 1.5 mm and a composite, kink-resistant structure, and the fluid delivery system further comprising a plug having a body with a passage to receive the catheter body therethrough, the plug configured to be inserted into the fascia to protect against leakage of cerebrospinal fluid; and releasing the agent via the catheter into the intrathecal space.
- a method of treating a disorder selected from the group consisting of Huntington's disease, Spinal Muscular Atrophy (SMA), survival motor neuron (SMN) deficiency, amyotrophic lateral sclerosis (ALS), Angelman's Syndrome, Dravet Syndrome, Alzheimer's disease, progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), Parkinson's Disease, central nervous system (CNS) lymphoma, and Leptomeningeal Cancer in a patient in need thereof includes implanting a fluid delivery system in the patient such that a catheter of the fluid delivery system is disposed within the patient's intrathecal space, the catheter characterized by a catheter body having an outer diameter in the range of about 0.25 mm to 1.5 mm and a composite, kink-resistant structure, and the fluid delivery system further comprising a plug having a body with a passage to receive the catheter body therethrough, the plug configured to be inserted into the fascia to protect against leak
- a fluid delivery system in accordance with a third aspect, includes a port implantable to a subcutaneous location.
- a body of the port defines a chamber having an open top and a delivery opening
- a septum of the port is disposed on the body and includes a lower surface that extends over the open top of the chamber and an opposite, upper surface
- a cap of the port defines an opening extending therethrough.
- the cap is configured to be coupled to the body to secure the septum within the port with the opening providing needle access to the septum and the cap includes a downwardly tapered surface extending around the opening and configured to direct a needle towards the upper surface of the septum.
- the fluid delivery system further includes a catheter connection portion of the body.
- a fluid delivery system in accordance with a fourth aspect, includes a port that is implantable to a subcutaneous location secured to a bony structure of a patient.
- a body of the port defines a chamber that has an open top and a delivery opening, a septum of the port is disposed on the body to extend over the open top of the chamber, and a cap of the port is configured to be coupled to the body to secure the septum within the port.
- the cap defines an opening extending therethrough, such that with the cap coupled to the body, the opening provides needle access to the septum.
- the above fluid delivery systems can include one or more of the following features: one or more of the body, septum, cap, or catheter can be radiopaque; the cap can include a downwardly tapered surface extending around the opening; the port can include raised protrusions that are configured to provide palpatory feedback; the port can include outwardly protruding suture plugs that are configured to provide palpatory feedback; the port can include a raised lip that extends around the septum, and that system can include a guide tool that has a profile that is configured to mate with the raised lip through tissue to provide an external location detector for the septum; the port can include an actuator having a movable portion to provide at least one of tactile or visual feedback in response to actuation; piezoelectric crystals that are mounted to the port and configured to vibrate in response to an electric field introduced by an external instrument and, optionally, one or more LEDs mounted to the port and electrically coupled to the piezoelectric crystals to energize in response to palpation of the piezoelectric crystal
- the fluid delivery system can further include a catheter that has a proximal end configured to be coupled to the body to be fluidly coupled to the delivery opening of the chamber and a distal end having an outlet.
- the catheter can include radially oriented outlets disposed along a length thereof in a spiral configuration; the catheter can include radiopaque markings at one or more of: adjacent to the distal tip, above a start of the spiral configuration, below an end of the spiral configuration; the catheter can have a 3 layer construction including an inner lumen, a reinforcement layer, and an outer jacket; the distal end of the catheter can include an atraumatic tip; or the distal end of the catheter can include side passages for flow mass amplification.
- a catheter can be coupled to the port by any of the following: the delivery opening can include a cylindrical cavity having a connection portion, which can be one of a threaded portion, a snap-fit recess, or a luer lock recess, and the system can include a gasket disposed over the catheter proximal end and a fastener configured to engage the connection portion of the cylindrical cavity to compress the compression member to secure the catheter proximal end within the cylindrical cavity; the port can include an outlet tube extending from the delivery opening of the chamber, the catheter proximal end can have an annular configuration sized to have the outlet tube inserted therein and the system can further include a compression member, which can be one of a compression spring, a compression fitting, or an o-ring, disposed around the catheter proximal end and outlet tube to secure the catheter to the port; the port can include an outlet tube extending from the delivery opening of the chamber, the catheter proximal end and the outlet tube can have a lap joint connection, and the system
- the fluid delivery system can further include one or more dosages of a therapeutic agent, as described further below.
- a method for implanting a fluid delivery port and a catheter in an intrathecal space of a patient includes mounting the port to a bony structure within a subcutaneous space of the patient, disposing a distal tip of the catheter in the intrathecal space, tunneling a proximal end of the catheter under the skin of the patient to the port, and connecting the proximal end of the catheter to the port.
- connecting the proximal end of the catheter to the port can include inserting the proximal end of the catheter into an annular gasket, inserting the proximal end of the catheter and the compression member into a cylindrical outlet cavity of the port, and inserting a fastener into the cylindrical outlet cavity of the port to longitudinally compress the gasket and secure the proximal end of the catheter to the port.
- connecting the proximal end of the catheter to the port can include disposing the proximal end of the catheter over an outlet tube of the port and securing the catheter to the outlet tube with a compression member disposed over the catheter.
- locating the port can include one or more of the following: imaging radiopaque portions of the port; palpating raised protrusions of the port; palpating suture plugs coupled to the port; mating a guide tool with a raised lip of the port; actuating an actuator having a movable portion providing at least one of tactile or visual feedback; emitting an electric field to vibrate piezoelectric crystals mounted to the port; attracting a metallic guide to one or more magnets distributed about the septum within the port; attracting a magnetic guide to one or more metallic portions distributed about the septum of the port; imaging metallic and non-metallic components of the port; illuminating one or more LEDs mounted to the port; communicating with one or more sensors disposed within the port with an external device to provide one or more of: distance, alignment, orientation, targeting, or location data relative to the external device; or detecting an aqueous gel material within the port by ultrasound.
- dispensing the composition into the chamber can include dispensing one or more therapeutic agents described further below.
- FIG. 1 is a perspective view of a first example port for a fluid delivery system in accordance with various embodiments
- FIG. 2 is a cross-sectional view of the port of FIG. 1 showing an interior chamber and catheter connection assembly in accordance with various embodiments;
- FIG. 3 is a perspective view of a second example port for a fluid delivery system in accordance with various embodiments
- FIG. 4 is a cross-section view of the port of FIG. 3 showing an interior chamber and catheter connection assembly in accordance with various embodiments;
- FIG. 5 is a bottom perspective view of the port of FIG. 3 in accordance with various embodiments.
- FIG. 6 is a cross-sectional vie of the port of FIG. 3 showing fastener connections between a body and cap of the port in accordance with various embodiments;
- FIG. 7 is a schematic view of a fluid delivery system in accordance with various embodiments.
- FIG. 8 is a top plan view of a port for a fluid delivery system having a first example body configuration for location feedback in accordance with various embodiments;
- FIG. 9 is a top plan view of a port for a fluid delivery system having a second example body configuration for location feedback in accordance with various embodiments.
- FIG. 10 is a top plan view of a port for a fluid delivery system having a third example body configuration for location feedback in accordance with various embodiments;
- FIG. 11 is a top plan view of a port for a fluid delivery system having a fourth example body configuration for location feedback in accordance with various embodiments;
- FIG. 12 is a perspective view of a first example port for a fluid delivery system having location feedback features in accordance with various embodiments
- FIG. 13 is a perspective view of a second example port for a fluid delivery system having location feedback features in accordance with various embodiments
- FIG. 14 is a perspective view of a third example port for a fluid delivery system having location feedback features in accordance with various embodiments
- FIG. 15 is a perspective view of a fourth example port for a fluid delivery system having location feedback features in accordance with various embodiments
- FIG. 16 is a top plan view of a fifth example port for a fluid delivery system having location feedback features in accordance with various embodiments;
- FIG. 17 is a side view of the port of FIG. 16 showing first and second states of a lever of the port in accordance with various embodiments;
- FIG. 18 is a top plan view of a sixth example port for a fluid delivery system having location feedback features in accordance with various embodiments;
- FIG. 19 is a top plan view of a seventh example port for a fluid delivery system having location feedback features in accordance with various embodiments;
- FIG. 20 is a top plan view of a eighth example port for a fluid delivery system having location feedback features with an external device in accordance with various embodiments;
- FIG. 21 is a side elevational view of the port of FIG. 20 in accordance with various embodiments.
- FIG. 22 is a top plan view of a ninth example port for a fluid delivery system having location feedback features in accordance with various embodiments;
- FIG. 23 is a perspective view of a tenth example port for a fluid delivery system having location feedback features with an external guide in accordance with various embodiments;
- FIG. 24 is a top plan view of an eleventh example port for a fluid delivery system having location feedback features in accordance with various embodiments;
- FIG. 25 is a side elevational view of the port of FIG. 24 with an external metallic guide in accordance with various embodiments;
- FIG. 26 is a perspective view of a twelfth example port for a fluid delivery system having location feedback features with an external magnetic guide in accordance with various embodiments;
- FIG. 27 is a side elevational view of a thirteenth example port for a fluid delivery system having location feedback features with an external metal detector in accordance with various embodiments;
- FIG. 28 is a perspective view of a fourteenth example port for a fluid delivery system having location feedback features in accordance with various embodiments
- FIG. 29 is a perspective view of a fifteenth example port for a fluid delivery system having location feedback features with an external device in accordance with various embodiments;
- FIG. 30 is a top plan view of a sixteenth example port for a fluid delivery system having location feedback features in accordance with various embodiments;
- FIG. 31 is a side plan view of the port of FIG. 30 in accordance with various embodiments.
- FIG. 32 is a perspective view of the port of FIG. 30 with an external device in accordance with various embodiments;
- FIG. 33 is a top plan view of a fluid delivery system including a port and catheter in accordance with various embodiments
- FIG. 34 a is a cross-sectional view of a catheter having a first example construction in accordance with various embodiments
- FIG. 34 b is a cross-sectional view of a catheter having a second example construction in accordance with various embodiments
- FIG. 35 a is a schematic view of a fluid delivery system for implantation in the intrathecal space of a patient and portion of a catheter of the fluid delivery system in accordance with various embodiments;
- FIG. 35 b is a schematic view of a catheter inserted into a dura of a patient with a grommet extending around the catheter and engaging the dura in accordance with various embodiments;
- FIG. 35 c is a cross-sectional view of a plug for a catheter inserted into the fascia in accordance with various embodiments
- FIG. 35 d is a perspective view of the plug of FIG. 35 c in accordance with various embodiments.
- FIG. 36 is a sectional view of a distal end of the catheter of FIG. 34 in accordance with various embodiments;
- FIG. 37 a is a cross-sectional view of a first example distal end for a catheter in accordance with various embodiments
- FIG. 37 b is a cross-sectional view of a second example distal end for a catheter in accordance with various embodiments.
- FIG. 37 c is a cross-sectional view of a third example distal end for a catheter in accordance with various embodiments.
- FIG. 37 d is a cross-sectional view of a fourth example distal end for a catheter in accordance with various embodiments.
- FIG. 38 a is a sectional view of an intermediate portion of the catheter of FIG. 34 showing first example radial outlets in accordance with various embodiments;
- FIG. 38 b is a sectional view of a portion of a catheter showing second example radial outlets in accordance with various embodiments;
- FIG. 38 c is a sectional view of a portion of a catheter showing third example radial outlets in accordance with various embodiments;
- FIG. 38 d is a sectional view of a portion of a catheter showing fourth example radial outlets in accordance with various embodiments;
- FIG. 39 is a cross-sectional view of a first example catheter and port connection assembly in accordance with various embodiments.
- FIG. 40 is a cross-sectional view of a second example catheter and port connection assembly in accordance with various embodiments.
- FIG. 41 is a cross-sectional view of a third example catheter and port connection assembly in accordance with various embodiments.
- FIG. 42 is a cross-sectional view of a fourth example catheter and port connection assembly in accordance with various embodiments.
- FIG. 43 is a cross-sectional view of a fifth example catheter and port connection assembly in accordance with various embodiments.
- FIG. 44 is a cross-sectional view of a sixth example catheter and port connection assembly in accordance with various embodiments.
- FIG. 45 is a cross-sectional view of a seventh example catheter and port connection assembly in accordance with various embodiments.
- FIG. 46 is a cross-sectional view of an eighth example catheter and port connection assembly in accordance with various embodiments.
- FIG. 47 is a cross-sectional view of a ninth example catheter and port connection assembly in accordance with various embodiments.
- FIG. 48 is a cross-sectional view of a tenth catheter and port connection assembly in accordance with various embodiments.
- FIG. 49 is a cross-sectional view of an eleventh example catheter and port connection assembly in accordance with various embodiments.
- FIG. 50 is a cross-sectional view of an example port for a fluid delivery system having a side septum for a stylet in accordance with various embodiments.
- FIG. 51 is a cross-sectional view of an example port for a fluid delivery system being impregnated or pre-loaded with one or more dosages of a medication in accordance with various embodiments.
- the fluid delivery devices, systems and methods described herein include a sterile, implantable intrathecal catheter and subcutaneous port.
- the fluid delivery devices are designed to facilitate intrathecal access in patients with normal spines, as well as patients with spinal deformities and/or instrumentation for whom intrathecal access, and the associated fluid administration and sampling, via lumbar puncture (LP) is complicated or not possible.
- LP lumbar puncture
- the fluid delivery systems can be used to administer fluids (optionally including one or more therapeutic agents) to patients by means of manual bolus injection, standard syringe pump or Pulsar auto-injector pump.
- Therapeutics approved for bolus intrathecal administration would be infused into the patient through the subcutaneous port by palpating the port to identify the septum, and accessing the septum with a needle, such as a standard non-coring Huber needle.
- a needle such as a standard non-coring Huber needle.
- the system can include a non-invasive detection guide.
- the systems can utilize magnetic components, sensors, light sources, and/or transmitters to provide location aid to a clinician.
- the port 100 includes a body 102 , a cap 104 coupled to the body 102 , and a septum 106 providing needle access to a chamber 108 defined in the body 102 .
- the chamber 108 includes a delivery opening 110 to dispense fluids to desired areas, described in more detail below.
- the port 100 can be anchored on a desired location within a patient selected by a clinician, such as a bony structure.
- the body 102 can include one or more openings 112 extending therethrough to receive fasteners to mount the port 100 to the bony structure.
- the openings 112 can be recessed with respect to adjacent portions of the body 102 , so that head portions of the fasteners do not protrude beyond the body surface or only a portion thereof protrudes beyond the body surface.
- the port 100 can have a tapered profile with smooth exterior surfaces. This configuration advantageously mitigates skin erosion when the port 100 is implanted in a desired subcutaneous location.
- the body 102 has a frusto-conical shape with an outwardly tapering exterior surface 114 extending from an upper shoulder surface 116 to a bottom wall portion 118 .
- the body 102 defines an interior cavity 120 having an opening 122 opposite the bottom wall portion 118 .
- the body 102 extends around the interior cavity 120 in an annular configuration.
- the interior cavity 120 includes a lower portion defining the chamber 108 and an upper septum receiving portion 124 .
- the chamber 108 can have smaller cross-sectional dimensions than the upper portion 124 , such that a shoulder 126 extends between the upper portion 124 and the chamber 108 of the interior cavity 120 .
- the upper portion 124 and the chamber 108 are cylindrical with the chamber 108 having a smaller diameter than the upper portion 124 .
- the upper portion 124 is sized to receive the septum 106 therein.
- the septum 106 can have a disk shaped configuration and the diameter of the upper portion 124 can be approximately equal to, e.g., within 2 mm, to the diameter of the septum 106 so that the septum 106 is securely received within the upper portion 124 .
- the shoulder 126 can include an upwardly projecting lip 128 that extends around an interior edge thereof and is configured to engage the septum 106 .
- the cap 104 is coupled to the body 102 to trap the septum 106 therebetween.
- the cap 104 defines an interior opening 130 extending therethrough to provide needle access to the septum 106 .
- the cap 104 is annular with a generally triangular cross-section in a longitudinal direction. So configured, the cap 104 includes an interior surface 132 that extends around and tapers downwardly toward the opening 130 , an exterior surface 134 that tapers downwardly to the body 102 , and a top edge 135 .
- the cap 104 extends over an upper surface of the septum 106 , with the cap 104 deforming the septum 106 and causing the upper surface of the septum 106 to protrude through the opening 130 .
- the interior surface 132 can advantageously redirect a needle that has missed the septum 106 to the opening 130 and to the upper surface of the septum 106 .
- the cap 104 can further include a downwardly extending sidewall 136 that defines a portion of the exterior surface 134 and that projects along the body 102 .
- the body 102 includes an outwardly opening groove 138 in the exterior surface 114 and the sidewall 136 of the cap 104 includes an inwardly projecting lip 140 .
- the cap 104 can be press fit onto the body 102 , deflecting the sidewall 136 until the lip 140 snap fits into the groove 138 .
- the cap 104 With the cap 104 secured to the body 102 , the cap 104 has an annular portion 142 extending over the cavity opening 122 and, in some versions, includes a downwardly projecting lip 144 extending therearound.
- an outer portion 146 of the septum 106 is trapped between the annular portion 142 of the cap 104 and the shoulder 126 of the body 102 , while a central portion 148 of the septum 106 provides a clear path to the chamber 108 .
- the lips 128 , 144 project towards one another on opposite sides of the septum 106 to pinch the septum 106 therebetween to both secure the septum 106 and ensure a fluid tight seal.
- the thickness and diameter of the septum 106 can be optimized to provide a low-profile port 100 , while also providing a sufficiently large diameter for the central portion 148 so that the septum 106 can be easily located and identified through tissue.
- the cap 104 can also include an internal thread configured to engage an external thread of the body 102 to secure the cap 104 thereto.
- the cap 104 can be ultrasonically welded to the body 102 .
- FIGS. 3-6 Another example port 200 suitable for subcutaneous implantation is shown in FIGS. 3-6 .
- the port 200 of this form includes many similar features to the above described port 100 and, as such, only the differences will be described herein with components having similar reference characters.
- the port 200 of this form includes a body 202 , a cap 204 coupled to the body 202 , and a septum 206 providing needle access to a chamber 208 defined in the body 202 .
- the chamber 208 includes a delivery opening 210 to dispense fluids to desired areas, described in more detail below.
- the port 200 can be anchored on a desired location within a patient selected by a clinician, such as a bony structure.
- the cap 204 and body 202 couple together so that exterior surfaces 234 , 214 thereof align giving the port 200 a substantially unbroken exterior with a frusto-conical shape.
- the body 202 includes an intermediate upstanding wall portion 250 disposed between a shoulder 226 of a body cavity 220 and an exterior shoulder 252 .
- the cap 204 seats on the exterior shoulder 252 of the body 202 with an inwardly extending top portion 254 seating on an upper surface 216 of the wall 250 with an annular portion 242 engaging the septum 206 as described above.
- FIGS. 5 and 6 Another suitable method for securing the cap 204 to the body 202 is shown in FIGS. 5 and 6 .
- the body 202 includes a plurality of throughbores 256 extending therethrough and the cap 204 includes corresponding bores 258 that align with the throughbores 256 of the body 202 .
- fasteners 260 can be inserted through the bottom wall 218 of the body 202 and secured to the cap 204 , such as by threading as shown.
- the annular portion 242 of the cap 104 and the shoulder 126 of the body 202 traps the outer portion 246 of the septum 106 therebetween, while providing a clear path to the chamber 208 through the central portion 248 of the septum 206 .
- the body 202 can include counterbores 262 in the bottom wall 218 thereof so that heads 264 of the fasteners 260 do not protrude beyond the bottom wall 218 .
- the components of the port 100 , 200 can be formed from any suitable material.
- one or more of the body 102 , 202 , cap 104 , 204 , septum 106 , 206 , or portions thereof, can be radiopaque for easy visualization under a fluoroscope or in an x-ray.
- inner structures of the port 100 , 200 can be polyether ether ketone (PEEK) or can have a PEEK layer on a metal housing, such as Titanium.
- an outer shell, or needle facing surfaces can be metal, such as Titanium.
- the port 100 , 200 can include one or more features to aid in locating the port 100 , 200 in a subcutaneous position.
- a clinician can palpate and visually inspect the tissue of patient in order to locate the port 100 , 200 .
- the body 102 , 202 can include a housing 300 having a distinctive shape providing palpatory feedback to a clinician through the tissue of patient.
- the housing 300 can have an oval or track-shaped cross-section as shown in FIG. 8 , can have three or more outwardly extending branches 302 as shown in FIG. 9 , can have a triangular cross-section as shown in FIG. 10 , or can have an oval or track-shaped cross-section with a prong 304 extending outwardly from a side edge 306 thereof as shown in FIG. 11 .
- the port 100 , 200 can include protruding features 310 providing distinct palpatory feedback to a clinician through the tissue of a patient by virtue of differences in surface height as compared to adjacent portions of the cap 104 , 204 and/or body 102 , 202 .
- the cap 104 , 204 can include a plurality of raised protrusions 312 extending above the top edge 135 , 235 thereof and distributed around the opening 130 , 230 as shown in FIGS. 12-14 .
- the raised protrusions 312 can be disposed on the top edge 135 , 235 , the interior surface 132 , 232 , the exterior surface 134 , 234 , or combinations thereof.
- the raised protrusions 312 can take any suitable form, including rounded nodes as shown in FIG. 12 , arcs as shown in FIG. 13 , and a raised wall or lip as shown in FIG. 14 .
- the features 310 can have a rounded or rectangular profile and can be provided in any suitable amount, such as four as shown in the figures, two, three, five, six, or more.
- the protruding features 310 have been described with reference to the cap 104 , 204 , the body 102 , 202 can also or alternatively include similarly configured protruding features 310 .
- the port 100 , 200 can include upwardly protruding suture plugs 314 , which can be filled with silicone, to provide palpatory feedback to a clinician through the tissue of patient.
- a base 316 of the suture plugs 314 can be mounted to the body 102 , 202 and distributed around the central septum 106 , 206 with a shaft 318 extending upwardly from the base 316 having a distal end 320 disposed above the top edge 135 , 235 of the cap 104 , 204 .
- the suture plugs 314 can have any suitable cross-section, such as circular or rectangular, and can be provided in any suitable amount, such as four as shown in the figures, two, three, five, six, or more.
- the cap 104 , 204 can also or alternatively include similarly configured suture plugs 314 .
- the port 100 , 200 can include a lever 322 pivotable about a pin 324 .
- the lever 322 is disposed within a recess 326 within the cap 104 , 204 or body 102 , 202 and has an angled configuration, so that a portion 328 is always projecting out of the recess 326 .
- a clinician can manipulate the lever 322 and the pivoting action of the lever 322 will provide tactile and visual feedback through the tissue.
- the port 100 , 200 can include a switch 330 , such as a pushbutton or slide switch. Actuation of the switch 330 can provide tactile feedback to a clinician.
- the switch 330 can be electrically coupled to an LED or other light source 332 , such that actuation of the switch 330 energizes the LED 332 providing visual feedback to a clinician upon actuation.
- the lever 322 , recess 326 , switch 330 , and/or LED 332 can be encapsulated or covered with a protective layer 334 adhered or otherwise secured to the port 100 , 200 to prevent tissue from interfering with the feedback response and movement of the components.
- the port 100 , 200 can include a plurality of LEDs or other light sources 336 embedded into the body 102 , 202 and/or cap 104 , 204 .
- the LEDs 336 can be electrically coupled together and to a first coil 338 . So configured, a clinician can bring an external device 340 having a second coil 342 emitting an electromagnetic field into range of the first coil 338 to transfer energy and thereby energize the LEDs 336 providing visual feedback to the clinician.
- the LEDs 336 can be disposed around the opening 130 , 230 and directed inwardly to selectively illuminate the septum 106 , 206 .
- the LEDs 336 can be disposed around the opening 130 and directed upwardly to selectively provide illumination through the tissue of the patient. Any number of LEDs 336 can be utilized, such as four or five as shown, two, three, six, or more.
- the port 100 , 200 can include a plurality of piezoelectric crystals 344 embedded into the body 102 , 202 and/or cap 104 , 204 .
- a clinician can bring an external device 346 emitting an electric field into range of the piezoelectric crystals 344 to cause the piezoelectric crystals 344 to vibrate and provide tactical and visual feedback to the clinician.
- the piezoelectric crystals 344 can be distributed around the opening 130 , 230 and sized to protrude from adjacent surfaces of the body 102 , 202 and/or cap 104 , 204 to provide tactile feedback similar to the above-described protruding features 310 .
- the piezoelectric crystals 344 can extend past the top edge 135 , 235 of the cap 104 , 204 .
- the port 100 , 200 can include a plurality of LEDs or other light sources 348 embedded into the body 102 , 202 and/or cap 104 , 204 .
- the LEDs 348 can be electrically coupled together and to the piezoelectric crystals 344 . So configured, a clinician can find the piezoelectric crystals 344 through vibration and subsequently palpate the piezoelectric crystals 344 to emit a voltage and energize the LEDs 348 .
- the LEDs 348 can be configured to illuminate the septum 106 , 206 and/or outwardly as described above with respect to FIGS. 18 and 19 .
- the top edge 135 , 235 of the cap 104 , 204 can have a raised lip 350 and an external guide 352 can include a central opening 354 configured to mate with and around the raised lip 350 .
- the external guide 352 can further include a skirt 356 depending downwardly from the central opening 354 so that a profile of the skirt 356 is complementary to external surfaces 114 , 214 , 134 , 234 of the body 102 , 202 and cap 104 , 204 .
- a clinician can locate the port 100 , 200 and place the guide 352 onto the port 100 , 200 through the tissue of the patient and the opening 354 and skirt 356 will orient the guide 352 to non-invasively identify the location of the septum 106 , 206 through the opening 354 .
- the port 100 , 200 can include a plurality of magnets 358 embedded into the body 102 , 202 and/or cap 104 , 204 and distributed around the opening 130 , 230 . So configured, a clinician can bring an external metallic ring 360 into range of the magnets 358 and the magnets 358 will attract the ring 360 to the port 100 , 200 through the tissue of the patient. The magnets 358 orient the ring 360 to frame the opening 130 , 230 on top of the tissue of the patient to provide an external indication of the location of the septum 106 , 206 . Any number of magnets 358 can be utilized, such as three as shown, two, four, five, six, or more, to optimize the strength and locationing of the guide 352 .
- the port 100 , 200 can include a metallic ring 362 extending around the opening 130 , 230 and mounted to or forming a portion of the body 102 , 202 , and/or cap 104 , 204 .
- a metallic ring 362 extending around the opening 130 , 230 and mounted to or forming a portion of the body 102 , 202 , and/or cap 104 , 204 .
- an unbroken ring 362 is shown, it will be understood that the ring 362 can be formed from a plurality of spaced portions.
- a clinician can bring an external magnetic guide 364 having an interior opening 366 into range of the metallic ring 362 and the magnetic guide 364 will be attracted to the metallic ring 362 of the port 100 , 200 through the tissue of the patient.
- the magnetic guide 364 is then oriented and held on the tissue of the patient so that the opening 366 frames the opening 130 , 230 to provide an external indication of the location of the septum 106 , 206 .
- the magnetic guide 364 can be formed entirely of a magnetic material or can include a plurality of magnets mounted thereto. Any number of magnets can be utilized to optimize the strength and locationing of the guide 364 .
- the port 100 , 200 can include metallic portions or components 368 of a sufficient size to be detectable by an external metal detector 370 .
- a clinician can operate the metal detector 370 and move the detector 370 along the patient's body until the detector 370 indicates the presence of the metallic components 368 . Thereafter, the clinician can palpate the tissue to identify the location of the septum 106 , 206 .
- the metallic components 368 can be fasteners, layers, or portions of the body 102 , 202 and/or cap 104 , 204 .
- the port 100 , 200 can include a transmitter 372 can be passive and energized by an external device 370 with a receiver 374 , such as that described above with respect to FIGS. 18 and 19 . So configured, the can operate the device 370 and move the device 370 along the patient's body until the device 370 energizes the transmitter 372 and receives a signal from the transmitter 372 . Thereafter, the clinician can palpate the tissue to identify the location of the septum 106 , 206 .
- the port 100 , 200 can include a combination of metallic and non-metallic components to provide distinct appearance under imaging.
- the port 100 , 200 can include rings of metallic and non-metallic portions
- the body 102 , 202 can be metallic
- the cap 104 , 204 can be metallic, or combinations thereof.
- the septum 106 , 206 can be radiopaque so that a clinician can clearly distinguish between the various components and the location of the septum 106 , 206 under imaging.
- the septum 106 , 206 can be filled with aqueous gel materials that are detectable by an ultrasound machine.
- the port 100 , 200 can be configured so that the septum 106 , 206 can be raised through the central opening 130 , 230 .
- the septum 106 , 206 can be raised by a lifting mechanism 376 disposed within the port 100 , 200 and engaging the septum 106 , 206 .
- the lifting mechanism 376 can be any suitable device, including actuators, springs, motors, magnets, and so forth.
- the lifting mechanism 376 can be operable in response to communication or influence by an external tool 378 .
- the tool 378 can send a wireless command to the lifting mechanism 376 and/or can include metallic or magnetic components.
- the septum 106 , 206 can be lifted to a raised position as shown to provide visible and tactile feedback to a clinician for locating the port 100 , 200 . Further, the raised septum 106 , 206 can be utilized during infusion, described in more detail below.
- the port 100 , 200 can include one or more sensors 380 embedded within the body 102 , 202 and/or cap 104 , 204 thereof.
- the sensors 380 can be passive and energized by an external device 382 , such as that described above with respect to FIGS. 18 and 19 .
- the external device 382 can include a housing 384 with corresponding sensors 386 and a processor 388 .
- the sensors 380 , 386 can be one or more of: proximity, infrared, pressure, ultrasonic, light, temperature, or tilt sensors.
- the sensors 380 , 386 can provide data to the processor 388 of the external device 382 regarding the distance, axis alignment, orientation, relative angles, or combinations of the sensors 386 of the external device 382 relative to the sensors 380 of the port 100 , 200 .
- the sensors 380 , 386 can identify vertical alignment or misalignment therebetween, shown by vertical alignment X 1 and angled alignment X 2 in FIG. 32 . Further, readings from the sensors 380 , 386 can identify horizontal alignment, shown by the angle X 3 in FIG. 32 .
- the processor 388 can then analyze the data to calculate a position and/or orientation of the external device 382 relative to the port 100 , 200 and provide feedback to a clinician.
- the external device 382 can provide feedback by any suitable mechanism, such as through lights 390 , sounds through a speaker 392 , a vibration device 394 , or any other visual or tactile feedback to indicate that the external device 382 is properly aligned with the port 100 , 200 for optimized needle insertion into and through the septum 106 , 206 .
- the external device 382 can utilize multicolored lights 390 or other distinguishable feedback to communicate degrees of accuracy with different designated colors for alignment, such as red for misalignment, yellow for near alignment, and green for correct alignment.
- a catheter 400 can be coupled to the port 100 , 200 to be fluidly coupled to the delivery opening 110 of the chamber 108 to dispense fluids to desired areas.
- the catheter 400 can be utilized to provide homogeneous delivery of composition (optionally comprising one or more therapeutic agents) to the intrathecal space of a patient.
- the catheter 400 can be configured to extend along the substantially the entire length of a patient's spinal column or along any portion thereof.
- the catheter 400 includes an elongate, tubular body 402 having a central passage 404 extending from a proximal end 406 configured to couple to the port 100 , 200 to a distal end 408 .
- the catheter 400 can be configured for long term implantation into a patient and, as such, can be constructed from materials to make the catheter soft, flexible, and kink resistant. Further, in some versions, the catheter 400 can be configured to complex spine patients, e.g., scoliosis, the materials can provide column strength, break resistance, and stiffness so that the catheter 400 can be threadable during insertion. Pursuant to this, some or all of the catheter 400 can have a three layer construction as shown in FIGS. 34 a and 34 b , including an inner lumen 410 , a reinforcement layer 412 , and an outer jacket 414 .
- the inner lumen 410 can be polytetrafluoroethylene (PTFE) or polyurethane (PU) and the outer jacket 414 can be an extrusion of PTSE, PU, or silicone and can include a hydrophilic coating.
- the reinforcement layer 412 can be provided in the proximal end 406 to increase a hoop strength of the catheter 400 allowing a relatively higher compression without crushing damage, which may compromise the interior diameter of the catheter 400 . This can advantageously be utilized to provide a strong connection and seal with the port 100 , 200 , several examples of which are described below. In a first example, as shown in FIG.
- the reinforcement layer 412 can be a suitable braided metal, such as stainless steel, or polymer, such as polyimide, polyethylene terephthalate (PET), and so forth.
- the reinforcement layer 412 can be a series of rings or a coil causing the catheter to have outwardly extending radial protrusions 413 .
- the radial protrusions 413 can be utilized in the connection with the port 100 , 200 , described in more detail below, subsidize the tensile strength of the connection.
- the distal end 408 of the catheter 400 can include an atraumatic tip 416 having a rounded profile and a distal outlet 418 extending therethrough to the central passage 404 .
- the distal outlet 418 can be disposed along a longitudinal axis of the catheter 400 or can be disposed at an angle with respect thereto.
- the rounded profile of the atraumatic tip 416 allows the distal end 408 to be easily deflectable during insertion to avoid the end 408 from becoming lodged and aid in the catheter 400 being threaded through the intrathecal space. Further, the atraumatic tip 416 can allow implantation into the intrathecal space without damaging or exiting the intrathecal space.
- FIG. 37 a One example atraumatic tip 416 is shown in FIG. 37 a .
- the tip 416 of this form includes a narrowing choke 420 connecting the central passage 404 to the distal outlet 418 where the choke 420 has a smaller diameter than the central passage 404 and distal outlet 418 creating a venturi effect, lowering fluid pressure and increasing fluid velocity through the tip 416 .
- the distal outlet 418 can include a mixing chamber 428 having an inner diameter that is equal to or larger than the inner diameter of the central passage 404 .
- the distal outlet 418 can include a reduced-diameter opening 430 relative to the inner diameter of the mixing chamber 428 .
- the opening 430 gives the distal outlet 418 a nozzle effect.
- the tip 416 includes one or more side passages 422 , such as two, three, four, or more, that extend from radial openings 424 to fluidly connect to the distal outlet 418 .
- the side passages 422 can extend at an angle with respect to the longitudinal axis of the catheter 400 so that interior openings 426 of the side passages 422 are closer to the distal end 408 of the catheter 400 than the radial openings 424 .
- the choke 420 creates a higher flow of therapeutic fluid through the catheter 400 with a lower pressure. Due to this, cerebrospinal fluid is drawn into the catheter 400 through the side passages 422 to join the flow of fluid creating a higher mass flow.
- the side passages 422 can serve as secondary outlets for the catheter distal end 408 .
- the distal outlet 418 includes a mixing chamber 432 having an inner diameter larger than the inner diameter of the central passage 404 and a radially-tapering transition portion 434 extending between the central passage 404 and the mixing chamber 432 .
- the distal outlet 418 can have a constant inner diameter extending from the mixing chamber to an outlet opening 436 .
- the tip 416 can further include one or more side passages 438 , such as two, three, four, or more, configured similar to the side passages 422 of the above form extending at an angle with respect to the longitudinal axis of the catheter.
- the side passages 438 can connect to the transition portion 434 to introduce cerebrospinal fluid to the flow of fluid through the catheter 400 providing flow mass amplification within the mixing chamber 432 .
- FIG. 37 c Another example atraumatic tip 416 is shown in FIG. 37 c that includes side passages 440 and a narrowing choke 442 .
- the side passages 440 extend radially through the catheter 400 and connect to the central passage 404 in the choke 442 .
- the inner diameter of the central passage 404 and an outlet opening 444 can be generally equal.
- the distal outlet 418 can include a reduced-diameter opening 446 relative to the inner diameter of the central passage 404 .
- the opening 446 gives the distal outlet 418 a nozzle effect.
- the catheter 400 can include one or more radial outlets 448 disposed along a length of the catheter 400 between the proximal and distal ends 406 , 408 thereof.
- the radial outlets 448 can be disposed in a spiral configuration extending along a length and around a circumference of the catheter 400 . The spiral configuration of this form ensures that the composition has a maximized exposure and spread within the intrathecal space.
- the radial outlets 448 can be disposed in one or more rings 450 with the radial outlets 448 distributed about a circumference of the catheter 400 .
- the rings 450 can be spaced from one another along the axial length of the catheter 400 and can be disposed within a plane generally normal to the axial length of the catheter 400 .
- the radial outlets 448 can be disposed in one or more bands 452 running the axial length of the catheter 400 .
- the catheter 400 can include one band 452 to distribute fluid in one radial direction, two, three, four, or more, as desired.
- the radial outlets 448 can include both one or more rings 450 and one or more bands 452 .
- the distal and radial outlets 418 , 448 can be sized to achieve a desired fluid distribution.
- the distal and radial outlets 418 , 448 can be sized so that a majority of fluid is dispensed through the distal outlet 418 .
- the distal and radial outlets 418 , 448 can be sized so that an amount of fluid dispensed through the distal outlet 418 is generally equal to an amount of fluid dispensed through the radial outlets 448 .
- the catheter 400 may include one or more radiopaque markings or components to be visible under imaging.
- the entire catheter 400 can be radiopaque or, as shown in FIG. 35 a , the catheter 400 can include radiopaque markings 454 disposed at featured locations, such as below the distal end 406 , adjacent to a start of the radial outlets 448 , adjacent to an end of the radial outlets 448 , and so forth.
- the catheter 400 can be provided with an extended length so that a clinician can cut the catheter 400 to a desired length for a particular patient.
- the catheter 400 can be provided to the clinician with a length up to 140 cm.
- the catheter 400 described herein can be a 3-fr, 1 mm outer diameter catheter.
- Other suitable outer diameters for the catheter 400 can be in the range of about 0.25 mm to about 1.5 mm, or in the range of about 0.5 mm to about 1.25 mm, or in the range of about 0.75 mm to about 1.0 mm.
- the spinal column of a patient is surrounded by a dura 458 that can be penetrated by a suitable instrument, such as a Tuohy needle, to create an opening 456 for the insertion of a catheter 400 , configured as described above.
- a clinician can utilize a grommet 460 to abut the dura 458 and extend around the opening 456 therein.
- the grommet 460 can include a sleeve portion 462 sized to extend around the catheter 400 and a flange portion 464 projecting outwardly from the sleeve portion 462 and configured to be placed on the dura 458 over and around the opening 456 .
- the catheter 400 can further be provided or implanted along with a plug 466 having a body 468 with a passage 470 extending therethrough for reception of the catheter 400 .
- the passage 470 extends through the plug body 468 from a distal end 472 to an opposite, proximal end 474 thereof.
- one or both of the ends 472 , 474 can have a beveled, frusto-conical configuration.
- the body 468 can have a bent configuration with the distal end 472 at an angle with respect to the proximal end 474 .
- the body 468 can include a bend 476 , that can be generally 90 degrees, e.g., within 5 to 10 degrees, as shown, although other acute or obtuse angles can also be utilized.
- the body 468 can include an opening 478 that extends through the body 468 from the passage 470 to an exterior 480 of the plug 466 .
- a clinician can utilize the opening 478 to manipulate the catheter 400 through the plug body 468 and out through the distal end 472 .
- a fascia 482 extends around the dura 458 and, as such, the fascia 482 can also be penetrated by the instrument to create an opening 484 therein in addition to the opening 456 in the dura 458 .
- the plug 466 can advantageously be implanted through the opening 484 in the fascia 482 to create a seal with the tissue of the fascia 482 to minimize or prevent leakage of cerebrospinal fluid.
- the beveled configuration of the distal end 472 can also aid a clinician in inserting the plug 466 through the fascia 482 .
- the plug 466 can be inserted into the fascia 482 until the distal end 472 abuts the dura 458 . So configured, the distal end 472 can extend around the opening 456 to minimize or prevent tearing and cerebrospinal fluid leakage.
- the plug 466 can be inserted into the fascia 482 with the distal end 472 spaced from the dura 458 . In either approach, after the plug 466 is positioned, a clinician can stitch up the opening 484 in the fascia 482 with a suture 486 so that some tissue 488 of the suture 486 is captured between the suture 486 and the plug body 468 .
- the plug body 468 can include an annular recess 490 extending therearound, or a plurality of recesses distributed around the circumference, adjacent to the distal end 472 .
- the tissue 488 can be drawn into the recess 488 preventing or minimizing subsequent movement of the suture 486 .
- the body 468 can further include outwardly projecting tabs 492 having openings 494 extending therethough.
- a clinician can utilize the tabs 492 to secure the proximal end 474 of the plug body 468 to the fascia 482 with sutures 492 .
- the bent configuration of the body 468 allows the plug proximal end 474 to extend along the fascia 482 for a compact configuration after implantation.
- the plug 466 can be made of silicone or other suitable material.
- the catheter 400 can include a portion with an outwardly tapered configuration where the increased outer diameter is configured to engage the opening 456 in the dura 458 to minimize or prevent tearing.
- the catheter 400 can be configured to couple to the port 100 , 200 to be fluidly coupled to the delivery opening 110 , 210 of the chamber 108 , 208 .
- This can be achieved in a number of suitable connection assemblies 500 , some or all of which can advantageously be free of metal components.
- the port 100 , 200 can include a cylindrical cavity 502 extending radially through the body 102 , 202 with the delivery opening 110 , 210 at an interior end 504 and an open exterior end 506 .
- the cylindrical cavity 502 can include a threaded portion 508 and a counterbore 510 at the open exterior end 506 .
- an annular gasket 512 can be placed over the proximal end 406 of the catheter 400 and the assembled gasket 512 and catheter 400 is inserted into the cavity 502 until the gasket 512 and catheter 400 abut the interior end 504 thereof. As shown, this aligns the central passage 404 of the catheter 400 with the delivery opening 110 , 210 .
- a ferrule 514 extending around the catheter 400 can be inserted into the cavity 502 to engage the threaded portion 508 .
- the counterbore 510 can be sized to receive a portion of a head 516 of the ferrule 514 to minimize outwardly protruding features on the port 100 , 200 .
- the gasket 512 can be a singular component or can be composed of multiple components, as desired.
- the inner diameter of the gasket 512 can be larger than an outer diameter of the catheter 400 .
- the proximal end 406 of the catheter 400 can be reinforced to have a higher hoop strength to withstand the compressive force generated by the gasket 512 .
- the ferrule 514 and/or cavity 502 can include a torque limiting tool to prevent overtightening and the possible resulting damage to the catheter 400 .
- the cavity 502 can include a catheter counterbore 518 at the interior end 504 thereof.
- the catheter counterbore 518 has a diameter sized to receive a portion of the proximal end 406 of the catheter 400 therein, but also sized to be smaller than the gasket 512 . With this configuration, the end of the catheter 400 is not compressed by the gasket 512 during tightening and therefore possible crushing of the end is prevented.
- the assembly 500 can utilize a snap-fit connection rather than a threaded connection as described above with respect to FIGS. 2, 4, and 39 .
- the cavity 502 can include an annular snap-fit recess 520 having a radially outward stop surface 522 and a ferrule 524 can include an outwardly projecting annular prong 526 . So configured, the ferrule 524 , extending around the catheter 400 , can be inserted into the cavity 502 until the prong 526 is biased into the recess 520 by the resiliency of the ferrule 524 and/or the catheter 400 .
- the prong 526 engages the stop surface 522 of the recess 520 , preventing removal of the ferrule 524 .
- the recess 520 can be located within the cavity 502 and the gasket 512 can be sized to provide an optimal amount of compression to result in a fluid tight seal without overly compressing the catheter 400 .
- the recess 520 and prong 526 are described as annular, discrete portions that can be aligned during insertion is within the scope of this disclosure.
- the assembly 500 can utilize a luer lock connection rather than a threaded or snap-fit connection as described above.
- the cavity 502 can include a plurality of radial recesses 528 with outwardly extending openings 530 .
- a ferrule 532 of this form can include a plurality of radial tabs 534 that are positioned to align with the openings 530 .
- the tabs 534 and openings 530 can be symmetrically disposed around the ferrule 532 and cavity 502 respectively.
- a clinician can align the tabs 534 with the openings 530 , insert the ferrule 532 into the cavity 502 until the tabs 534 align with the radial recesses 528 , and turn the ferrule 532 a predetermined amount, such as a quarter turn, to lock the ferrule 532 to the port 100 , 200 .
- the radial recesses 528 can be sized to frictionally engage the tabs 534 .
- the radial recesses 528 can be located within the cavity 502 and the gasket 512 can be sized to provide an optimal amount of compression to result in a fluid tight seal without overly compressing the catheter 400 .
- the port 100 , 200 can include an outwardly projecting tube 536 having a passage 538 extending from the delivery opening 110 , 210 of the chamber 108 , 208 .
- the tube 536 can have an outer diameter that is equal to or smaller than an inner diameter of the catheter proximal end 406 so that the proximal end 406 can be inserted over and around the tube 536 .
- a spring 540 which can be made of metal, such as nitinol, for example, having a resting state compressing the catheter 400 , can be twisted to loosen the spring 540 to allow the catheter proximal end 406 to be inserted onto the tube 536 and released to compress and secure the catheter 400 to the port 100 , 200 .
- a clinician can utilize a tool to engage the spring 540 to easily loosen the windings thereof during assembly.
- the outwardly projecting tube 536 can include a backstop 542 extending around an intermediate portion thereof and the catheter proximal end 406 can have a press-fit ring 544 mounted thereto.
- the catheter proximal end 406 can have an expanded diameter to secure within the ring 544 and an interior opening 546 of the ring 544 can be sized to have a press-fit engagement with the tube 536 . So configured, a clinician can simply align the opening 546 with the tube 536 and press the ring 544 until the ring 544 abuts the backstop 542 .
- the port 100 , 200 can include an annular wall 548 encircling the tube 536 .
- the assembly 500 of this form can further include an o-ring 550 having an inner diameter smaller than an outer diameter of the catheter proximal end 406 such that the o-ring 550 provides a compressive force on the catheter 400 when mounted therearound.
- the o-ring 550 can be shifted longitudinally along the catheter 400 so that the proximal end 406 can be fully inserted between the tube 536 and wall 548 . Thereafter, the o-ring 550 can be stretched or rolled onto the wall 548 to provide a compressive force through the wall 548 to the catheter 400 and tube 536 .
- the inner diameter of the wall 548 can be generally equal, within 1 mm, of an outer diameter of the catheter 400 so that the catheter 400 is tightly received in the annular space between the wall 548 and tube 536 .
- the o-ring 550 can be formed from rubber or any suitable elastomer, for example.
- the assembly 500 of this form can utilize a clamping member 552 to secure the catheter proximal end 406 to the tube 536 .
- the clamping member 552 can include upper and lower portions 554 , 556 that are movable with respect to one another to be clamped around the catheter proximal end 406 and the tube 536 during assembly.
- the catheter proximal end 406 and the tube 536 can be axially aligned in a lap joint connection so that the ends thereof abut one another and the clamping member 552 can be secured thereover to provide a fluid tight seal.
- the upper and lower portions 554 , 556 can be secured together by any suitable mechanism, including snap-fit, crimping, an attachment member, and so forth.
- the port 100 , 200 can include an annular wall 558 encircling the tube 536 creating an annular catheter reception space 560 between the wall 558 and tube 536 .
- the catheter proximal end 406 of this form can have an enlarged outer diameter as compared to the main body of the catheter 400 , such that the proximal end 406 has greater hoop strength and can withstand greater compressive forces during assembly.
- the reception space 560 can be sized to receive the catheter proximal end 406 therein in a compressive, press-fit configuration to secure the catheter 400 to the port 100 , 200 and form a fluid tight seal between the tube 536 and catheter 400 .
- the port 100 , 200 can include a pre-connected assembly 562 including a flexible tube 564 secured to the body 102 , 202 and fluidly connected to the delivery opening 110 , 210 and a connector 566 .
- the connector 566 includes a central stem 568 and surrounding housing 570 that define an annular catheter reception space 572 therebetween. So configured, during assembly a clinician can insert the catheter proximal end 406 into the reception space 572 to fluidly couple the catheter 400 to the port 100 , 200 .
- the coupling can utilize a press-fit as described above, or can utilize an o-ring 574 on the housing 570 in similar configuration as described above with respect to FIG. 43 to provide a compressive force on the catheter 400 and stem 568 .
- the port 100 , 200 can include a connection member 576 having a base 578 and an outwardly projecting stem 580 , which can be made of metal, such as titanium, for example,
- the connection member 576 includes a passage 582 therethrough that is fluidly coupled to the delivery opening 110 , 210 .
- the stem 580 can include barbs 583 that extend outwardly from an intermediate portion thereof to engage and retain the catheter proximal end 406 after assembly.
- the assembly 500 of this form can further include a plastic housing 584 extending around the connection member 576 to engage the outer jacket 414 of the catheter 400 .
- a clinician can insert the catheter proximal end 406 over the stem 580 until the catheter 400 abuts the base 578 .
- the barbs 583 and housing 584 provide a compressive force on the catheter 400 to secure the catheter 400 to the port 100 , 200 .
- the tube 536 can have an outer diameter that is larger than an inner diameter of the catheter 400 and the catheter proximal end 406 can be flexible to be stretched over the tube 536 during assembly.
- the tube 536 can include a radial lip or barb 586 extending therearound to retain the stretched catheter end 406 on the tube 536 .
- the assembly 500 can further include a rigid or resilient sleeve 588 that extends along the flexible length of the catheter 400 to prevent the flexible portion from becoming kinked.
- the port 100 , 200 can include a side septum assembly 600 so that a stylet 602 can be pre-loaded and provided with the port 100 , 200 .
- the side septum assembly 600 includes a radial cavity 604 extending between the chamber 108 , 208 and the exterior 114 , 214 of the body 102 , 202 and a septum 606 received within the cavity 604 .
- the cavity 604 includes an outwardly projecting recess 608 to receive a flange portion 610 of the septum 606 to prevent or minimize movement of the septum 606 while the style 602 is moved therethrough.
- the side septum assembly 600 can advantageously be located across the chamber 108 , 208 from the delivery opening 110 , 210 so that the stylet 602 can be easily threaded therethrough. Further, the side septum assembly 600 can be utilized with any of the catheter connection assemblies 500 described above.
- One example method for implanting the fluid delivery systems described herein includes selecting a suitable bony structure of a patient for implantation of the port 100 , 200 and securing the port 100 , 200 to the bony structure by any suitable method.
- the method can further include a clinician placing the distal end 408 of the catheter 400 in the intrathecal space of a patient, utilizing the features and properties of the catheter 400 to tunnel the proximal end 406 of the catheter 400 under the skin within the intrathecal space to the subcutaneously implanted port 100 , 200 , and connecting the catheter 400 to the port 100 , 200 via any of the connection assemblies 500 described herein.
- a clinician can utilize the fluid delivery system to sample cerebrospinal fluid for diagnostic purposes or can utilize the system to deliver a composition (e.g., a dose of a therapeutic agent) to the intrathecal space of the patient.
- a composition e.g., a dose of a therapeutic agent
- the clinician can locate the subcutaneous port 100 , 200 using any of the above-described features.
- a clinician can use a Huber needle attached to a standard syringe containing the composition and, manually, using a standard syringe pump, or using Pulsar auto-injector pump, slowly inject the composition into the chamber 108 , 210 to dispense the composition through the outlets 418 , 428 of the catheter 400 into the intrathecal space of the patient.
- the medication can be delivered as bolus or per infusion algorithm from the Pulsar pump using the Pulsar auto-injector pump.
- an approved dosing regimen of the therapeutic agent may require removal of cerebrospinal fluid before injection of the therapeutic agent, which can be done manually, using a standard syringe pump, or using Pulsar auto injector pump from the port 100 , 200 via the non-coring Huber needle attached to a syringe.
- the syringe can also be loaded to a Pulsar auto injector pump.
- the port 100 , 200 , and the chamber 108 , 208 thereof, can be configured so that there is minimal dead volume for the composition.
- the dead volume of the port 100 , 200 can be between about 1.0 mL and no dead volume, and, in one form, about 0.5 mL.
- the chamber 108 , 208 of the port 100 , 200 can be impregnated or pre-loaded with one or more dosages 650 of a therapeutic agent.
- a clinician can dispense one of the doses 650 by applying pressure to the septum 106 , 206 or other movable portion of the port 100 , 200 to force the dose 650 through the delivery opening 110 , 210 and into the catheter 400 .
- the dosages 650 can be separated by movable doors 652 extending across the chamber 108 , 208 .
- the doors 652 can be metallic and be selectively and non-invasively moved by a clinician using an external device 654 having one or more magnets therein.
- the fluid delivery systems described herein can further be provided as a set, which can include an implantation kit/introducer, anchoring components for the catheter 400 , and/or a facial anchor. Further, if desired, a filter can be provided in the catheter, delivery opening 110 , 210 , or chamber 108 , 208 .
- the device described herein is suitable for administering any fluid composition, such as a pharmaceutical composition comprising one or more therapeutic agents, to a subject.
- the device of the disclosure optionally comprises one or more dosages of a therapeutic agent, such as a therapeutic agent suitable for treating (in whole or in part) a disorder, infection, or injury of the central nervous system or spine.
- disorders associated with aspects of the central nervous system or spine include, but are not limited to, spinal muscular atrophy, survival motor neuron deficiency, ankylosing spondylitis, spinal tumors, bipolar disorder, encephalitis, depression, epilepsy, Dravet Syndrome, meningitis, multiple sclerosis, myeopathy, Angelman's Syndrome, CNS lymphoma, Leptomeningeal cancer, Friedreich's Ataxia, hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D), cerebral amyloid angiopathy (CAA), amyloid congophilic angiopathy (ACA), and secondary malignant neoplasms (SMN), or neurodegenerative disorders, e.g., Tau protein-related disorders including Alzheimer's disease, Huntington's disease, alpha-synuclei-related disorders including Parkinson's disease, amyotrophic lateral sclerosis (ALS) including superoxide dismutase 1-related ALS,
- any therapeutic agent may be used in the context of the disclosure.
- exemplary therapeutic agents include, e.g., nucleic acids, protein therapeutics, cell therapies, and small molecule therapeutics.
- protein therapeutics include antibody-based therapeutics, such as antibodies, antibody fragments, or antibody-like protein products that include binding regions of antibodies (e.g., scFv, diabodies, antibody mimetics, and the like).
- the antibody-based therapeutic may target, e.g., amyloid plaques, tau proteins, cancer antigens, or abnormal alpha-synuclein.
- protein therapeutics also include, but are not limited to, hormones, enzymes (e.g., lysosomal enzymes, such as alpha-L-iduronidase, N-acetylgalactosamine-4-sulfatase, or beta-glucuronidase), growth factors (e.g., fibroblast growth factor (FGF) or neurotrophins or neurotrophic factors, such as glial cell-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), or nerve growth factor (NGF)), blood factors, bone morphogenetic proteins, interferons, interleukins, and thrombolytics.
- enzymes e.g., lysosomal enzymes, such as alpha-L-iduronidase, N-acetylgalactosamine-4-sulfatase, or beta-glucuronidase
- growth factors e.g., fibroblast growth factor (FGF
- cell-based therapies include, but are not limited to, stem cell therapeutics and immune cells (including modified immune cells, such as CAR T cells).
- Suitable small molecule therapeutics include, but are not limited to, analgesics, ion channel blockers, anti-convulsive agents, antibiotics or antiviral agents, anti-inflammatories, anticoagulants, chemotherapeutic, anti-depressants, anti-anxiety agents, steroids, and the like.
- the therapeutic agent is baclofen, morphine, bupivacaine hydrochloride, clonidine hydrochloride, gabapentin, idursulfase, cytarabine, methotrexate, a corticosteroid, edavarone-conjugate, conotoxin, abomorphine, prednisolone hemisuccinate sodium, carbidopa/levodopa, tetrabenazine, benzodiazepines, such as diazepam and midazolam, alphaxalone or other derivative, cyclophosphamide, idursulfase (Elaprase®), iduronidase (Aldurazyme®), topotecan, buslfan, opmaveloxolone, epicatechin, methylprednisolone, frataxin replacement, reservatrol, nicontinamide, AT-010 (RNA that induce
- the therapeutic agent is a nucleic acid, including DNA or RNA, which may be single stranded or double stranded and which may be modified or unmodified.
- Suitable nucleic acid-based therapeutic agents include, but are not limited to, antisense oligonucleotides, ribozymes, miRNA, siRNA, and shRNA.
- the nucleic acid targets a gene selected from the group consisting of APP, MAPT, SOD1, BACE1, CASP3, TGM2, TARDBP, ADRB1, CAMK2A, CBLN1, CDK5R1, GABRA1, MAPK10, NOS1, NPTX2, NRGN, NTS, PDCD2, PDE4D, PENK, SYT1, TTR, FUS, LRDD, CYBA, ATF3, CASP2, HRK, C1QBP, BNIP3, MAPK8, MAPK14, Rac1, GSK3B, P2RX7, TRPM2, PARG, CD38, STEAP4, BMP2, GJA1, TYROBP, CTGF, ANXA2, DUOX1, RTP801, RTP801L, NOX4, NOX1, NOX2 (gp91pho, CYBB), NOX5, DUOX2, NOXO1, NOXO2 (p47phox, NCF1), NOXA1, NOXA2 (p67phox,
- the therapeutic agent is an oligonucleotide comprising at least one modified nucleotide, optionally a modified nucleotide that reduces binding to cerebral spinal fluid (CSF) proteins.
- the modified nucleotide includes a substituent at the 2′-position, such as a 2′-O-2-methoxyethyl (“2′-MOE”) group, as shown below, wherein X is O or S.
- Oligonucleotides comprising a 2′-MOE modification can distribute rapidly in central nervous system tissues. Oligonucleotides comprising such modifications exhibit extended half-lives in CSF and central nervous system tissues, which can result in less frequent dose administration.
- the modified nucleotide can include a 2,4-constrained group, such as a constrained 2-O-ethyl (“cEt”) group.
- cEt constrained 2-O-ethyl
- the cEt group can have S-stereochemistry (“S-cEt”), as shown below, wherein X is 0 or S.
- Nucleic acids modified with a constrained ethyl group can exhibit enhanced thermal stability, good potency, and a good therapeutic profile.
- the nucleic acid encodes a beneficial protein that, e.g., replaces an absent or defective protein, or encodes a cytotoxic protein that achieves a therapeutic effect, such as cancer cell death.
- a beneficial protein that, e.g., replaces an absent or defective protein, or encodes a cytotoxic protein that achieves a therapeutic effect, such as cancer cell death.
- Any of the protein-based therapeutics described herein may be delivered to a subject via delivery of a nucleic acid encoding the protein under conditions which allow expression in vivo.
- the nucleic acid encodes a neurotrophic factor such as, but not limited to, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5), neurotrophin-6 (NT-6), ciliary neurotrophic factor (CNTF), glial cell line-derived neurotrophic factor (GDNF), the fibroblast growth factor family (e.g., FGF 1-15), leukemia inhibitory factor (LIF), certain members of the insulin-like growth factor family (e.g., IGF-1), a neurturin, persephin, a bone morphogenic protein (BMPs), an immunophilin, a member of the transforming growth factor (TGF) family of growth factors, a neuregulin, epidermal growth factor (EGF), platelet-derived growth factor (PDGF), vascular endothelial growth factor family (e.g. VEGF 165), follistatin, or Hifl, or combinations
- the nucleic acid is present in a viral vector.
- Any viral vector appropriate for delivering a therapeutic agent to a human subject may be used.
- viral vectors include, e.g., herpes simplex virus (HSV) vectors, adenovirus (Ad) vectors, parvoviral-based vectors (e.g., adeno-associated viral vectors), chimeric Ad-AAV vectors, and retroviral vectors (including lentiviral vectors, HIV vectors).
- HSV herpes simplex virus
- Ad adenovirus
- parvoviral-based vectors e.g., adeno-associated viral vectors
- chimeric Ad-AAV vectors e.g., chimeric Ad-AAV vectors
- retroviral vectors including lentiviral vectors, HIV vectors.
- Any of these gene transfer vectors can be prepared using standard recombinant DNA techniques described in, e.g., Sambrook et al., Molecular
- the viral vector is an AAV vector.
- AAV vectors used for administration of a therapeutic nucleic acid typically have approximately 96% of the parental genome deleted, such that only the terminal repeats (ITRs), which contain recognition signals for DNA replication and packaging, remain.
- Delivering the AAV rep protein enables integration of the AAV vector comprising AAV ITRs into a specific region of genome, if desired.
- AAV vectors are useful for delivering payload to the central nervous system due, at least in part, to their safety profile, long-term gene expression, and ability to infect both dividing and quiescent cells, including neurons. Multiple serotypes of AAV exist and offer varied tissue tropism.
- Known serotypes include, for example, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10 and AAV11.
- AAV vectors may be engineered to alter the virus native tropism or improve infection by modifying the viral capsid or packaging the genome of one serotype into the capsid of a different serotype.
- AAV vectors have been used to deliver a number of transgenes to treat a variety of diseases, including ASP to treat Canavan disease; CLN2 to treat Late infantile neuronal ceroid lipofuscinosis; SGSH to treat mucopolysaccharidosis IIIA; NAGLU to treat mucopolysaccharidosis IIIB; ARSA to treat metachromatic leukodystrophy; GAD, AADC, NTN, GDNF, AADC to treat Parkinson®; and NGF to treat Alzheimer®. See, e.g., Hocquemiller et al., Hum Gene Ther., 27(7), 478-496 (2016), hereby incorporated by reference.
- the device is used to deliver one or more gene editing agents to a subject, such as the clustered regularly interspaced short palindromic repeats (CRISPR) associated protein (Cas) system.
- CRISPR-Cas and similar gene targeting systems are in the art with reagents and protocols readily available. See, e.g., Maliet al., Science, 339(6121), 823-826 (2013); and Hsu et al., Cell, 157.6: 1262-1278 (2014).
- the CRISPR/Cas system comprises a CRIPSR/Cas nuclease (typically Cas9) and guide RNA (or crRNA-tracrRNA) comprising a short nucleotide targeting sequence that directs the nuclease to a genome location of interest.
- the guide RNA(s) and coding sequence for the Cas nuclease can be delivered to the CSF via the device of the disclosure.
- the CRISPR/Cas system is further described in, e.g., U.S. Patent Publication Nos. 2018/0223311.
- the disclosure provides a method of treating Huntington's disease, Spinal Muscular Atrophy (SMA), survival motor neuron (SMN) deficiency, amyotrophic lateral sclerosis (ALS) (including superoxide dismutase 1 (SOD1)-related ALS), Angelman's syndrome, Dravet syndrome, Alzheimer's disease and other tau protein-related disorders, progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), alpha-synuclei-related disorders including Parkinson's Disease, central nervous system (CNS) lymphoma, leptomeningeal cancer, Friedreich's Ataxia, hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D), cerebral amyloid angiopathy (CAA), amyloid congophilic angiopathy (ACA), or secondary malignant neoplasms (SMN).
- SMA Spinal Muscular Atrophy
- SOD1 superoxide dismutase
- the method comprises implanting a fluid delivery system in the patient such that a catheter of the fluid delivery system is disposed within the patient's intrathecal space, the catheter characterized by a catheter body having an outer diameter in the range of about 0.25 mm to 1.5 mm and a composite, kink-resistant structure.
- the fluid delivery system further comprises a grommet having a sleeve portion extending around the catheter body and a flange portion to engage the dura of the patient over a catheter opening therein.
- the method further comprises releasing a therapeutic agent (such as any one or more of the therapeutic agents described above) via the catheter into the intrathecal space, such that the disorder is treated.
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 16/113,955, filed Aug. 27, 2018, which is hereby incorporated by reference herein in its entirety.
- The present disclosure generally relates to fluid delivery systems and, more particularly, to intrathecal fluid delivery systems.
- Intrathecal administration is a valuable tool for introducing therapeutic agents into the cerebral spinal fluid (CSF), which allows distribution throughout the central nervous system. Indeed, therapeutics administered to CSF are distributed to the brain and spinal cord, thereby avoiding potential delivery issues through the blood-brain barrier. Most drugs delivered to the CSF require multiple administrations, requiring at least periodic access to the intrathecal space over the course of a treatment regimen. Some individuals are unable to receive medication via lumbar puncture due to anatomical barriers, such as spinal deformities, and/or surgical interventions, such as implantation of stabilizing rods and spondylosis. Bone fusions, sharp angles, and instrumentation in these individuals complicate or prevent direct lumbar puncture entry into the intrathecal space because there is no space between the bones to allow safe puncture of the dura. In these patients, extraordinary means are often required to achieve intrathecal access; for example, an oscillating drill may be required to bore through the bone mass or a laminectomy procedure may be required, which heightens the risk associated with intrathecal administration. There remains a need in the art for a delivery system that allows repeated administration of substances to the intrathecal space.
- In accordance with one aspect, a fluid delivery system is disclosed that includes a port that is implantable to a subcutaneous location. The port includes a body that defines a chamber having an open top and a delivery opening and a septum coupled to the body to extend over the open top of the chamber. The fluid delivery system further includes an intrathecal catheter that has a proximal end that is configured to be coupled to the port and fluidly coupled to the delivery opening of the chamber, a distal end, a central passage extending between the proximal end and the distal end, and a distal outlet in the distal end. The fluid delivery system further includes a plug that has a body with a passage to receive the intrathecal catheter therethrough, where the plug is configured to be inserted into the fascia to protect against leakage of cerebrospinal fluid.
- According to some forms, that fluid delivery system can include one or more of the following aspects: the intrathecal catheter can include a plurality of radially oriented outlets, where the plurality of radially oriented outlets can be disposed along an axial length of the intrathecal catheter in a spiral configuration, the plurality of radially oriented outlets can include at least one of: one or more rings of outlets disposed within a plane normal to an axial length of the intrathecal catheter or a plurality of outlets aligned and spaced from one another along the axial length of the intrathecal catheter.
- According to some forms, the fluid delivery system can include one or more of the following aspects: the intrathecal catheter can be radiopaque; the intrathecal catheter can include radiopaque markings at one or more of: adjacent to the distal end, above a start of the plurality of radially oriented outlets, or below an end of the radially oriented outlets; at least a portion of the intrathecal catheter can have a 3 layer construction including an inner lumen, a reinforcement layer, and an outer jacket; the distal end of the intrathecal catheter can include an atraumatic tip allowing implantation without damaging or exiting the intrathecal space; the central passage can include a choked portion adjacent to the distal outlet to create a venturi effect with fluid being dispensed through the distal outlet; the distal end of the intrathecal catheter can include one or more side passages that fluidly couple the central passage to an exterior of the intrathecal catheter to draw in fluid from the exterior of the intrathecal catheter and provide flow mass amplification to fluid being dispensed through the distal outlet; the distal outlet can have a smaller diameter than an inner diameter of the central passage of the intrathecal catheter adjacent to the distal outlet; the central passage can have an increased inner diameter portion in the distal end of the intrathecal catheter relative to an intermediate portion of the central passage, where the increased inner diameter portion extends to the distal outlet; the intrathecal catheter can have an outer diameter in the range of about 0.25 mm to about 1.5 mm; the intrathecal catheter can include an outwardly tapered portion adjacent to the proximal end thereof, where the outwardly tapered portion is configured to engage the dura over the catheter opening therein; the proximal end of the intrathecal catheter can include a reinforcement material increasing the hoop strength of the proximal end, where the reinforcement material includes one or more of: a plurality of rings embedded within the intrathecal catheter proximal end, a coil embedded within the intrathecal catheter proximal end, a polymer tube embedded within the intrathecal catheter proximal end, or a braided material embedded within the intrathecal catheter proximal end.
- In accordance with a second aspect, a method of delivering an agent to a patient that has undergone a spinal stabilization or fusion procedure or suffers from a spinal deformity is disclosed that includes implanting a fluid delivery system in the patient such that a catheter of the fluid delivery system is disposed within the patient's intrathecal space, the catheter characterized by a catheter body having an outer diameter in the range of about 0.25 mm to 1.5 mm and a composite, kink-resistant structure, and the fluid delivery system further comprising a plug having a body with a passage to receive the catheter body therethrough, the plug configured to be inserted into the fascia to protect against leakage of cerebrospinal fluid; and releasing the agent via the catheter into the intrathecal space.
- In accordance with a third aspect, a method of treating a disorder selected from the group consisting of Huntington's disease, Spinal Muscular Atrophy (SMA), survival motor neuron (SMN) deficiency, amyotrophic lateral sclerosis (ALS), Angelman's Syndrome, Dravet Syndrome, Alzheimer's disease, progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), Parkinson's Disease, central nervous system (CNS) lymphoma, and Leptomeningeal Cancer in a patient in need thereof is disclosed that includes implanting a fluid delivery system in the patient such that a catheter of the fluid delivery system is disposed within the patient's intrathecal space, the catheter characterized by a catheter body having an outer diameter in the range of about 0.25 mm to 1.5 mm and a composite, kink-resistant structure, and the fluid delivery system further comprising a plug having a body with a passage to receive the catheter body therethrough, the plug configured to be inserted into the fascia to protect against leakage of cerebrospinal fluid; and releasing a therapeutic agent via the catheter into the intrathecal space such that the disorder is treated.
- In accordance with a third aspect, a fluid delivery system is disclosed that includes a port implantable to a subcutaneous location. A body of the port defines a chamber having an open top and a delivery opening, a septum of the port is disposed on the body and includes a lower surface that extends over the open top of the chamber and an opposite, upper surface, and a cap of the port defines an opening extending therethrough. The cap is configured to be coupled to the body to secure the septum within the port with the opening providing needle access to the septum and the cap includes a downwardly tapered surface extending around the opening and configured to direct a needle towards the upper surface of the septum. The fluid delivery system further includes a catheter connection portion of the body.
- In accordance with a fourth aspect, a fluid delivery system is described that includes a port that is implantable to a subcutaneous location secured to a bony structure of a patient. A body of the port defines a chamber that has an open top and a delivery opening, a septum of the port is disposed on the body to extend over the open top of the chamber, and a cap of the port is configured to be coupled to the body to secure the septum within the port. The cap defines an opening extending therethrough, such that with the cap coupled to the body, the opening provides needle access to the septum.
- According to some forms, the above fluid delivery systems can include one or more of the following features: one or more of the body, septum, cap, or catheter can be radiopaque; the cap can include a downwardly tapered surface extending around the opening; the port can include raised protrusions that are configured to provide palpatory feedback; the port can include outwardly protruding suture plugs that are configured to provide palpatory feedback; the port can include a raised lip that extends around the septum, and that system can include a guide tool that has a profile that is configured to mate with the raised lip through tissue to provide an external location detector for the septum; the port can include an actuator having a movable portion to provide at least one of tactile or visual feedback in response to actuation; piezoelectric crystals that are mounted to the port and configured to vibrate in response to an electric field introduced by an external instrument and, optionally, one or more LEDs mounted to the port and electrically coupled to the piezoelectric crystals to energize in response to palpation of the piezoelectric crystals; one or more magnets distributed about the septum within the port, and the system can include a metallic external guide that is attracted to the one or more magnets through tissue to provide a guide for needle access to the septum; the port can include metallic portions that are distributed about the septum, and that system can include a magnetic ring that is configured to magnetically couple to the metallic portions through tissue to provide a guide for needle access to the septum; the body and cap can include a combination of metallic and non-metallic components such that the body and cap are distinguishable under imaging; a plurality of LEDs mounted to the port to provide illumination through tissue of at least one of the septum or around the septum; one or more sensors disposed within the port to provide one or more of: distance, alignment, orientation, targeting, or location data relative to an external device in communication with the one or more sensors; the septum can include one or more internal cavities filled with an aqueous gel material detectable by ultrasound; the body can include a side opening to the chamber for a stylet and the system can further include a septum mounted within the side opening; or a therapeutic dose impregnated or pre-loaded in the port.
- According to additional forms, the fluid delivery system can further include a catheter that has a proximal end configured to be coupled to the body to be fluidly coupled to the delivery opening of the chamber and a distal end having an outlet. According to further forms, the catheter can include radially oriented outlets disposed along a length thereof in a spiral configuration; the catheter can include radiopaque markings at one or more of: adjacent to the distal tip, above a start of the spiral configuration, below an end of the spiral configuration; the catheter can have a 3 layer construction including an inner lumen, a reinforcement layer, and an outer jacket; the distal end of the catheter can include an atraumatic tip; or the distal end of the catheter can include side passages for flow mass amplification.
- According to further forms, a catheter can be coupled to the port by any of the following: the delivery opening can include a cylindrical cavity having a connection portion, which can be one of a threaded portion, a snap-fit recess, or a luer lock recess, and the system can include a gasket disposed over the catheter proximal end and a fastener configured to engage the connection portion of the cylindrical cavity to compress the compression member to secure the catheter proximal end within the cylindrical cavity; the port can include an outlet tube extending from the delivery opening of the chamber, the catheter proximal end can have an annular configuration sized to have the outlet tube inserted therein and the system can further include a compression member, which can be one of a compression spring, a compression fitting, or an o-ring, disposed around the catheter proximal end and outlet tube to secure the catheter to the port; the port can include an outlet tube extending from the delivery opening of the chamber, the catheter proximal end and the outlet tube can have a lap joint connection, and the system can further include a clamping member disposed over the lap joint connection to create fluid tight seal.
- According to any of the above forms, the fluid delivery system can further include one or more dosages of a therapeutic agent, as described further below.
- In accordance with a fifth aspect, a method for implanting a fluid delivery port and a catheter in an intrathecal space of a patient is described herein that includes mounting the port to a bony structure within a subcutaneous space of the patient, disposing a distal tip of the catheter in the intrathecal space, tunneling a proximal end of the catheter under the skin of the patient to the port, and connecting the proximal end of the catheter to the port.
- According to some forms, connecting the proximal end of the catheter to the port can include inserting the proximal end of the catheter into an annular gasket, inserting the proximal end of the catheter and the compression member into a cylindrical outlet cavity of the port, and inserting a fastener into the cylindrical outlet cavity of the port to longitudinally compress the gasket and secure the proximal end of the catheter to the port.
- According to other forms, connecting the proximal end of the catheter to the port can include disposing the proximal end of the catheter over an outlet tube of the port and securing the catheter to the outlet tube with a compression member disposed over the catheter.
- In accordance with a sixth aspect, a method for delivering a composition, such as a composition comprising a therapeutic agent, to an intrathecal space of a patient is described that includes locating a port secured in a subcutaneous position within a patient through tissue of the patient, inserting a distal tip of a needle through the tissue of the patient, through a septum of the port, and into a chamber of the port, dispensing the composition into the chamber, and distributing the composition into the intrathecal space of the patient through a catheter fluidly coupled to the port.
- According to some forms, locating the port can include one or more of the following: imaging radiopaque portions of the port; palpating raised protrusions of the port; palpating suture plugs coupled to the port; mating a guide tool with a raised lip of the port; actuating an actuator having a movable portion providing at least one of tactile or visual feedback; emitting an electric field to vibrate piezoelectric crystals mounted to the port; attracting a metallic guide to one or more magnets distributed about the septum within the port; attracting a magnetic guide to one or more metallic portions distributed about the septum of the port; imaging metallic and non-metallic components of the port; illuminating one or more LEDs mounted to the port; communicating with one or more sensors disposed within the port with an external device to provide one or more of: distance, alignment, orientation, targeting, or location data relative to the external device; or detecting an aqueous gel material within the port by ultrasound.
- According to some forms, dispensing the composition into the chamber can include dispensing one or more therapeutic agents described further below.
- The above needs are at least partially met through provision of the embodiments described in the following detailed description, particularly when studied in conjunction with the drawings, wherein:
-
FIG. 1 is a perspective view of a first example port for a fluid delivery system in accordance with various embodiments; -
FIG. 2 is a cross-sectional view of the port ofFIG. 1 showing an interior chamber and catheter connection assembly in accordance with various embodiments; -
FIG. 3 is a perspective view of a second example port for a fluid delivery system in accordance with various embodiments; -
FIG. 4 is a cross-section view of the port ofFIG. 3 showing an interior chamber and catheter connection assembly in accordance with various embodiments; -
FIG. 5 is a bottom perspective view of the port ofFIG. 3 in accordance with various embodiments; -
FIG. 6 is a cross-sectional vie of the port ofFIG. 3 showing fastener connections between a body and cap of the port in accordance with various embodiments; -
FIG. 7 is a schematic view of a fluid delivery system in accordance with various embodiments; -
FIG. 8 is a top plan view of a port for a fluid delivery system having a first example body configuration for location feedback in accordance with various embodiments; -
FIG. 9 is a top plan view of a port for a fluid delivery system having a second example body configuration for location feedback in accordance with various embodiments; -
FIG. 10 is a top plan view of a port for a fluid delivery system having a third example body configuration for location feedback in accordance with various embodiments; -
FIG. 11 is a top plan view of a port for a fluid delivery system having a fourth example body configuration for location feedback in accordance with various embodiments; -
FIG. 12 is a perspective view of a first example port for a fluid delivery system having location feedback features in accordance with various embodiments; -
FIG. 13 is a perspective view of a second example port for a fluid delivery system having location feedback features in accordance with various embodiments; -
FIG. 14 is a perspective view of a third example port for a fluid delivery system having location feedback features in accordance with various embodiments; -
FIG. 15 is a perspective view of a fourth example port for a fluid delivery system having location feedback features in accordance with various embodiments; -
FIG. 16 is a top plan view of a fifth example port for a fluid delivery system having location feedback features in accordance with various embodiments; -
FIG. 17 is a side view of the port ofFIG. 16 showing first and second states of a lever of the port in accordance with various embodiments; -
FIG. 18 is a top plan view of a sixth example port for a fluid delivery system having location feedback features in accordance with various embodiments; -
FIG. 19 is a top plan view of a seventh example port for a fluid delivery system having location feedback features in accordance with various embodiments; -
FIG. 20 is a top plan view of a eighth example port for a fluid delivery system having location feedback features with an external device in accordance with various embodiments; -
FIG. 21 is a side elevational view of the port ofFIG. 20 in accordance with various embodiments; -
FIG. 22 is a top plan view of a ninth example port for a fluid delivery system having location feedback features in accordance with various embodiments; -
FIG. 23 is a perspective view of a tenth example port for a fluid delivery system having location feedback features with an external guide in accordance with various embodiments; -
FIG. 24 is a top plan view of an eleventh example port for a fluid delivery system having location feedback features in accordance with various embodiments; -
FIG. 25 is a side elevational view of the port ofFIG. 24 with an external metallic guide in accordance with various embodiments; -
FIG. 26 is a perspective view of a twelfth example port for a fluid delivery system having location feedback features with an external magnetic guide in accordance with various embodiments; -
FIG. 27 is a side elevational view of a thirteenth example port for a fluid delivery system having location feedback features with an external metal detector in accordance with various embodiments; -
FIG. 28 is a perspective view of a fourteenth example port for a fluid delivery system having location feedback features in accordance with various embodiments; -
FIG. 29 is a perspective view of a fifteenth example port for a fluid delivery system having location feedback features with an external device in accordance with various embodiments; -
FIG. 30 is a top plan view of a sixteenth example port for a fluid delivery system having location feedback features in accordance with various embodiments; -
FIG. 31 is a side plan view of the port ofFIG. 30 in accordance with various embodiments; -
FIG. 32 is a perspective view of the port ofFIG. 30 with an external device in accordance with various embodiments; -
FIG. 33 is a top plan view of a fluid delivery system including a port and catheter in accordance with various embodiments; -
FIG. 34a is a cross-sectional view of a catheter having a first example construction in accordance with various embodiments; -
FIG. 34b is a cross-sectional view of a catheter having a second example construction in accordance with various embodiments; -
FIG. 35a is a schematic view of a fluid delivery system for implantation in the intrathecal space of a patient and portion of a catheter of the fluid delivery system in accordance with various embodiments; -
FIG. 35b is a schematic view of a catheter inserted into a dura of a patient with a grommet extending around the catheter and engaging the dura in accordance with various embodiments; -
FIG. 35c is a cross-sectional view of a plug for a catheter inserted into the fascia in accordance with various embodiments; -
FIG. 35d is a perspective view of the plug ofFIG. 35c in accordance with various embodiments; -
FIG. 36 is a sectional view of a distal end of the catheter ofFIG. 34 in accordance with various embodiments; -
FIG. 37a is a cross-sectional view of a first example distal end for a catheter in accordance with various embodiments; -
FIG. 37b is a cross-sectional view of a second example distal end for a catheter in accordance with various embodiments; -
FIG. 37c is a cross-sectional view of a third example distal end for a catheter in accordance with various embodiments; -
FIG. 37d is a cross-sectional view of a fourth example distal end for a catheter in accordance with various embodiments; -
FIG. 38a is a sectional view of an intermediate portion of the catheter ofFIG. 34 showing first example radial outlets in accordance with various embodiments; -
FIG. 38b is a sectional view of a portion of a catheter showing second example radial outlets in accordance with various embodiments; -
FIG. 38c is a sectional view of a portion of a catheter showing third example radial outlets in accordance with various embodiments; -
FIG. 38d is a sectional view of a portion of a catheter showing fourth example radial outlets in accordance with various embodiments; -
FIG. 39 is a cross-sectional view of a first example catheter and port connection assembly in accordance with various embodiments; -
FIG. 40 is a cross-sectional view of a second example catheter and port connection assembly in accordance with various embodiments; -
FIG. 41 is a cross-sectional view of a third example catheter and port connection assembly in accordance with various embodiments; -
FIG. 42 is a cross-sectional view of a fourth example catheter and port connection assembly in accordance with various embodiments; -
FIG. 43 is a cross-sectional view of a fifth example catheter and port connection assembly in accordance with various embodiments; -
FIG. 44 is a cross-sectional view of a sixth example catheter and port connection assembly in accordance with various embodiments; -
FIG. 45 is a cross-sectional view of a seventh example catheter and port connection assembly in accordance with various embodiments; -
FIG. 46 is a cross-sectional view of an eighth example catheter and port connection assembly in accordance with various embodiments; -
FIG. 47 is a cross-sectional view of a ninth example catheter and port connection assembly in accordance with various embodiments; -
FIG. 48 is a cross-sectional view of a tenth catheter and port connection assembly in accordance with various embodiments; -
FIG. 49 is a cross-sectional view of an eleventh example catheter and port connection assembly in accordance with various embodiments; -
FIG. 50 is a cross-sectional view of an example port for a fluid delivery system having a side septum for a stylet in accordance with various embodiments; and -
FIG. 51 is a cross-sectional view of an example port for a fluid delivery system being impregnated or pre-loaded with one or more dosages of a medication in accordance with various embodiments. - The fluid delivery devices, systems and methods described herein include a sterile, implantable intrathecal catheter and subcutaneous port. The fluid delivery devices are designed to facilitate intrathecal access in patients with normal spines, as well as patients with spinal deformities and/or instrumentation for whom intrathecal access, and the associated fluid administration and sampling, via lumbar puncture (LP) is complicated or not possible. By utilizing the devices, systems, and methods provided, the need for repeat anesthesia and surgery each time intrathecal access is needed in these patients can be avoided.
- The fluid delivery systems can be used to administer fluids (optionally including one or more therapeutic agents) to patients by means of manual bolus injection, standard syringe pump or Pulsar auto-injector pump. Therapeutics approved for bolus intrathecal administration would be infused into the patient through the subcutaneous port by palpating the port to identify the septum, and accessing the septum with a needle, such as a standard non-coring Huber needle. Additionally, or alternatively, the system can include a non-invasive detection guide. In some versions, the systems can utilize magnetic components, sensors, light sources, and/or transmitters to provide location aid to a clinician.
- An
example port 100 suitable for subcutaneous implantation is shown inFIGS. 1 and 2 . Theport 100 includes abody 102, acap 104 coupled to thebody 102, and aseptum 106 providing needle access to achamber 108 defined in thebody 102. Thechamber 108 includes adelivery opening 110 to dispense fluids to desired areas, described in more detail below. Theport 100 can be anchored on a desired location within a patient selected by a clinician, such as a bony structure. For example, thebody 102 can include one ormore openings 112 extending therethrough to receive fasteners to mount theport 100 to the bony structure. Further, theopenings 112 can be recessed with respect to adjacent portions of thebody 102, so that head portions of the fasteners do not protrude beyond the body surface or only a portion thereof protrudes beyond the body surface. As shown, theport 100 can have a tapered profile with smooth exterior surfaces. This configuration advantageously mitigates skin erosion when theport 100 is implanted in a desired subcutaneous location. - As shown in
FIG. 2 , thebody 102 has a frusto-conical shape with an outwardly taperingexterior surface 114 extending from anupper shoulder surface 116 to abottom wall portion 118. Thebody 102 defines aninterior cavity 120 having anopening 122 opposite thebottom wall portion 118. In the illustrated form, thebody 102 extends around theinterior cavity 120 in an annular configuration. Theinterior cavity 120 includes a lower portion defining thechamber 108 and an upperseptum receiving portion 124. Thechamber 108 can have smaller cross-sectional dimensions than theupper portion 124, such that ashoulder 126 extends between theupper portion 124 and thechamber 108 of theinterior cavity 120. In the illustrated form, theupper portion 124 and thechamber 108 are cylindrical with thechamber 108 having a smaller diameter than theupper portion 124. - The
upper portion 124 is sized to receive theseptum 106 therein. For example, theseptum 106 can have a disk shaped configuration and the diameter of theupper portion 124 can be approximately equal to, e.g., within 2 mm, to the diameter of theseptum 106 so that theseptum 106 is securely received within theupper portion 124. Further, as shown inFIG. 2 , theshoulder 126 can include an upwardly projectinglip 128 that extends around an interior edge thereof and is configured to engage theseptum 106. - In order to secure the
septum 106 within theport 100, thecap 104 is coupled to thebody 102 to trap theseptum 106 therebetween. Thecap 104 defines aninterior opening 130 extending therethrough to provide needle access to theseptum 106. In the illustrated form, thecap 104 is annular with a generally triangular cross-section in a longitudinal direction. So configured, thecap 104 includes aninterior surface 132 that extends around and tapers downwardly toward theopening 130, anexterior surface 134 that tapers downwardly to thebody 102, and atop edge 135. As shown, thecap 104 extends over an upper surface of theseptum 106, with thecap 104 deforming theseptum 106 and causing the upper surface of theseptum 106 to protrude through theopening 130. With this configuration, theinterior surface 132 can advantageously redirect a needle that has missed theseptum 106 to theopening 130 and to the upper surface of theseptum 106. - As shown, the
cap 104 can further include a downwardly extendingsidewall 136 that defines a portion of theexterior surface 134 and that projects along thebody 102. In the illustrated form, thebody 102 includes an outwardly openinggroove 138 in theexterior surface 114 and thesidewall 136 of thecap 104 includes an inwardly projectinglip 140. So configured, thecap 104 can be press fit onto thebody 102, deflecting thesidewall 136 until thelip 140 snap fits into thegroove 138. With thecap 104 secured to thebody 102, thecap 104 has anannular portion 142 extending over thecavity opening 122 and, in some versions, includes a downwardly projectinglip 144 extending therearound. So configured, anouter portion 146 of theseptum 106 is trapped between theannular portion 142 of thecap 104 and theshoulder 126 of thebody 102, while acentral portion 148 of theseptum 106 provides a clear path to thechamber 108. Thelips septum 106 to pinch theseptum 106 therebetween to both secure theseptum 106 and ensure a fluid tight seal. In some versions, the thickness and diameter of theseptum 106 can be optimized to provide a low-profile port 100, while also providing a sufficiently large diameter for thecentral portion 148 so that theseptum 106 can be easily located and identified through tissue. Alternatively, thecap 104 can also include an internal thread configured to engage an external thread of thebody 102 to secure thecap 104 thereto. In another example, thecap 104 can be ultrasonically welded to thebody 102. - Another
example port 200 suitable for subcutaneous implantation is shown inFIGS. 3-6 . Theport 200 of this form includes many similar features to the above describedport 100 and, as such, only the differences will be described herein with components having similar reference characters. For example, theport 200 of this form includes abody 202, acap 204 coupled to thebody 202, and aseptum 206 providing needle access to achamber 208 defined in thebody 202. Thechamber 208 includes adelivery opening 210 to dispense fluids to desired areas, described in more detail below. Theport 200 can be anchored on a desired location within a patient selected by a clinician, such as a bony structure. - In this form, the
cap 204 andbody 202 couple together so thatexterior surfaces FIG. 2 , thebody 202 includes an intermediateupstanding wall portion 250 disposed between ashoulder 226 of abody cavity 220 and anexterior shoulder 252. Thecap 204 seats on theexterior shoulder 252 of thebody 202 with an inwardly extendingtop portion 254 seating on anupper surface 216 of thewall 250 with anannular portion 242 engaging theseptum 206 as described above. - Another suitable method for securing the
cap 204 to thebody 202 is shown inFIGS. 5 and 6 . In this form, thebody 202 includes a plurality ofthroughbores 256 extending therethrough and thecap 204 includes correspondingbores 258 that align with thethroughbores 256 of thebody 202. So configured,fasteners 260 can be inserted through thebottom wall 218 of thebody 202 and secured to thecap 204, such as by threading as shown. As thefasteners 260 tighten, theannular portion 242 of thecap 104 and theshoulder 126 of thebody 202 traps theouter portion 246 of theseptum 106 therebetween, while providing a clear path to thechamber 208 through thecentral portion 248 of theseptum 206. If desired, thebody 202 can includecounterbores 262 in thebottom wall 218 thereof so that heads 264 of thefasteners 260 do not protrude beyond thebottom wall 218. - The components of the
port body cap septum port - As discussed above, the
port port FIG. 7 , a clinician can palpate and visually inspect the tissue of patient in order to locate theport body housing 300 having a distinctive shape providing palpatory feedback to a clinician through the tissue of patient. For example, thehousing 300 can have an oval or track-shaped cross-section as shown inFIG. 8 , can have three or more outwardly extendingbranches 302 as shown inFIG. 9 , can have a triangular cross-section as shown inFIG. 10 , or can have an oval or track-shaped cross-section with aprong 304 extending outwardly from aside edge 306 thereof as shown inFIG. 11 . - In another example, the
port cap body cap protrusions 312 extending above thetop edge opening FIGS. 12-14 . The raisedprotrusions 312 can be disposed on thetop edge interior surface exterior surface protrusions 312 can take any suitable form, including rounded nodes as shown inFIG. 12 , arcs as shown inFIG. 13 , and a raised wall or lip as shown inFIG. 14 . Thefeatures 310 can have a rounded or rectangular profile and can be provided in any suitable amount, such as four as shown in the figures, two, three, five, six, or more. Of course, while the protruding features 310 have been described with reference to thecap body - In another example, the
port FIG. 15 , abase 316 of the suture plugs 314 can be mounted to thebody central septum shaft 318 extending upwardly from the base 316 having adistal end 320 disposed above thetop edge cap body cap - In another example, as shown in
FIGS. 16 and 17 , theport lever 322 pivotable about apin 324. Thelever 322 is disposed within arecess 326 within thecap body portion 328 is always projecting out of therecess 326. With this configuration, a clinician can manipulate thelever 322 and the pivoting action of thelever 322 will provide tactile and visual feedback through the tissue. By another approach, theport switch 330, such as a pushbutton or slide switch. Actuation of theswitch 330 can provide tactile feedback to a clinician. Further, theswitch 330 can be electrically coupled to an LED or otherlight source 332, such that actuation of theswitch 330 energizes theLED 332 providing visual feedback to a clinician upon actuation. Thelever 322,recess 326,switch 330, and/orLED 332 can be encapsulated or covered with aprotective layer 334 adhered or otherwise secured to theport - In another example, as shown in
FIGS. 18 and 19 , theport light sources 336 embedded into thebody cap LEDs 336 can be electrically coupled together and to afirst coil 338. So configured, a clinician can bring anexternal device 340 having asecond coil 342 emitting an electromagnetic field into range of thefirst coil 338 to transfer energy and thereby energize theLEDs 336 providing visual feedback to the clinician. In a first form as shown inFIG. 18 , theLEDs 336 can be disposed around theopening septum FIG. 19 , theLEDs 336 can be disposed around theopening 130 and directed upwardly to selectively provide illumination through the tissue of the patient. Any number ofLEDs 336 can be utilized, such as four or five as shown, two, three, six, or more. - In another example, as shown in
FIG. 20 , theport piezoelectric crystals 344 embedded into thebody cap external device 346 emitting an electric field into range of thepiezoelectric crystals 344 to cause thepiezoelectric crystals 344 to vibrate and provide tactical and visual feedback to the clinician. If desired, as shown inFIG. 21 , thepiezoelectric crystals 344 can be distributed around theopening body cap piezoelectric crystals 344 can extend past thetop edge cap - Further, palpating the
piezoelectric crystals 344 causes thepiezoelectric crystals 344 to emit a voltage. Accordingly, as shown inFIG. 22 , theport light sources 348 embedded into thebody cap LEDs 348 can be electrically coupled together and to thepiezoelectric crystals 344. So configured, a clinician can find thepiezoelectric crystals 344 through vibration and subsequently palpate thepiezoelectric crystals 344 to emit a voltage and energize theLEDs 348. TheLEDs 348 can be configured to illuminate theseptum FIGS. 18 and 19 . - In another example, as shown in
FIG. 23 , thetop edge cap lip 350 and anexternal guide 352 can include acentral opening 354 configured to mate with and around the raisedlip 350. Theexternal guide 352 can further include askirt 356 depending downwardly from thecentral opening 354 so that a profile of theskirt 356 is complementary toexternal surfaces body cap port guide 352 onto theport opening 354 andskirt 356 will orient theguide 352 to non-invasively identify the location of theseptum opening 354. - In another example, as shown in
FIGS. 24 and 25 , theport magnets 358 embedded into thebody cap opening metallic ring 360 into range of themagnets 358 and themagnets 358 will attract thering 360 to theport magnets 358 orient thering 360 to frame theopening septum magnets 358 can be utilized, such as three as shown, two, four, five, six, or more, to optimize the strength and locationing of theguide 352. - In an alternative example, as shown in
FIG. 26 , theport metallic ring 362 extending around theopening body cap unbroken ring 362 is shown, it will be understood that thering 362 can be formed from a plurality of spaced portions. With this configuration, a clinician can bring an externalmagnetic guide 364 having aninterior opening 366 into range of themetallic ring 362 and themagnetic guide 364 will be attracted to themetallic ring 362 of theport magnetic guide 364 is then oriented and held on the tissue of the patient so that the opening 366 frames theopening septum magnetic guide 364 can be formed entirely of a magnetic material or can include a plurality of magnets mounted thereto. Any number of magnets can be utilized to optimize the strength and locationing of theguide 364. - In another example, as shown in
FIG. 27 , theport components 368 of a sufficient size to be detectable by anexternal metal detector 370. So configured, a clinician can operate themetal detector 370 and move thedetector 370 along the patient's body until thedetector 370 indicates the presence of themetallic components 368. Thereafter, the clinician can palpate the tissue to identify the location of theseptum metallic components 368 can be fasteners, layers, or portions of thebody cap port transmitter 372 can be passive and energized by anexternal device 370 with areceiver 374, such as that described above with respect toFIGS. 18 and 19 . So configured, the can operate thedevice 370 and move thedevice 370 along the patient's body until thedevice 370 energizes thetransmitter 372 and receives a signal from thetransmitter 372. Thereafter, the clinician can palpate the tissue to identify the location of theseptum - In an alternative example, as shown in
FIG. 28 , theport port body cap septum septum septum - In another example, as shown in
FIG. 29 , theport septum central opening septum lifting mechanism 376 disposed within theport septum lifting mechanism 376 can be any suitable device, including actuators, springs, motors, magnets, and so forth. Thelifting mechanism 376 can be operable in response to communication or influence by anexternal tool 378. For example, thetool 378 can send a wireless command to thelifting mechanism 376 and/or can include metallic or magnetic components. Theseptum port septum - In another example, as shown in
FIGS. 30-32 , theport more sensors 380 embedded within thebody cap sensors 380 can be passive and energized by anexternal device 382, such as that described above with respect toFIGS. 18 and 19 . Theexternal device 382 can include ahousing 384 withcorresponding sensors 386 and aprocessor 388. Thesensors sensors processor 388 of theexternal device 382 regarding the distance, axis alignment, orientation, relative angles, or combinations of thesensors 386 of theexternal device 382 relative to thesensors 380 of theport sensors FIG. 32 . Further, readings from thesensors FIG. 32 . Theprocessor 388 can then analyze the data to calculate a position and/or orientation of theexternal device 382 relative to theport external device 382 can provide feedback by any suitable mechanism, such as throughlights 390, sounds through aspeaker 392, avibration device 394, or any other visual or tactile feedback to indicate that theexternal device 382 is properly aligned with theport septum external device 382 can utilizemulticolored lights 390 or other distinguishable feedback to communicate degrees of accuracy with different designated colors for alignment, such as red for misalignment, yellow for near alignment, and green for correct alignment. - Turning now to
FIGS. 33-35 , acatheter 400 can be coupled to theport delivery opening 110 of thechamber 108 to dispense fluids to desired areas. Thecatheter 400 can be utilized to provide homogeneous delivery of composition (optionally comprising one or more therapeutic agents) to the intrathecal space of a patient. As such, thecatheter 400 can be configured to extend along the substantially the entire length of a patient's spinal column or along any portion thereof. As shown, thecatheter 400 includes an elongate,tubular body 402 having acentral passage 404 extending from aproximal end 406 configured to couple to theport distal end 408. - The
catheter 400 can be configured for long term implantation into a patient and, as such, can be constructed from materials to make the catheter soft, flexible, and kink resistant. Further, in some versions, thecatheter 400 can be configured to complex spine patients, e.g., scoliosis, the materials can provide column strength, break resistance, and stiffness so that thecatheter 400 can be threadable during insertion. Pursuant to this, some or all of thecatheter 400 can have a three layer construction as shown inFIGS. 34a and 34b , including aninner lumen 410, areinforcement layer 412, and anouter jacket 414. For example, theinner lumen 410 can be polytetrafluoroethylene (PTFE) or polyurethane (PU) and theouter jacket 414 can be an extrusion of PTSE, PU, or silicone and can include a hydrophilic coating. In some versions, thereinforcement layer 412 can be provided in theproximal end 406 to increase a hoop strength of thecatheter 400 allowing a relatively higher compression without crushing damage, which may compromise the interior diameter of thecatheter 400. This can advantageously be utilized to provide a strong connection and seal with theport FIG. 34a , thereinforcement layer 412 can be a suitable braided metal, such as stainless steel, or polymer, such as polyimide, polyethylene terephthalate (PET), and so forth. In a second example, as shown inFIG. 34b , thereinforcement layer 412 can be a series of rings or a coil causing the catheter to have outwardly extendingradial protrusions 413. Theradial protrusions 413 can be utilized in the connection with theport - As shown in
FIG. 36 , thedistal end 408 of thecatheter 400 can include anatraumatic tip 416 having a rounded profile and adistal outlet 418 extending therethrough to thecentral passage 404. Thedistal outlet 418 can be disposed along a longitudinal axis of thecatheter 400 or can be disposed at an angle with respect thereto. The rounded profile of theatraumatic tip 416 allows thedistal end 408 to be easily deflectable during insertion to avoid theend 408 from becoming lodged and aid in thecatheter 400 being threaded through the intrathecal space. Further, theatraumatic tip 416 can allow implantation into the intrathecal space without damaging or exiting the intrathecal space. - One example
atraumatic tip 416 is shown inFIG. 37a . Thetip 416 of this form includes a narrowingchoke 420 connecting thecentral passage 404 to thedistal outlet 418 where thechoke 420 has a smaller diameter than thecentral passage 404 anddistal outlet 418 creating a venturi effect, lowering fluid pressure and increasing fluid velocity through thetip 416. If desired, thedistal outlet 418 can include a mixingchamber 428 having an inner diameter that is equal to or larger than the inner diameter of thecentral passage 404. Further, thedistal outlet 418 can include a reduced-diameter opening 430 relative to the inner diameter of the mixingchamber 428. Theopening 430 gives the distal outlet 418 a nozzle effect. Further, thetip 416 includes one ormore side passages 422, such as two, three, four, or more, that extend fromradial openings 424 to fluidly connect to thedistal outlet 418. As shown, theside passages 422 can extend at an angle with respect to the longitudinal axis of thecatheter 400 so thatinterior openings 426 of theside passages 422 are closer to thedistal end 408 of thecatheter 400 than theradial openings 424. With this configuration, thechoke 420 creates a higher flow of therapeutic fluid through thecatheter 400 with a lower pressure. Due to this, cerebrospinal fluid is drawn into thecatheter 400 through theside passages 422 to join the flow of fluid creating a higher mass flow. Moreover, in the event that thedistal outlet 418 becomes blocked or occluded, theside passages 422 can serve as secondary outlets for the catheterdistal end 408. - Another example
atraumatic tip 416 is shown inFIG. 37b . In this form, thedistal outlet 418 includes a mixingchamber 432 having an inner diameter larger than the inner diameter of thecentral passage 404 and a radially-taperingtransition portion 434 extending between thecentral passage 404 and the mixingchamber 432. As shown, thedistal outlet 418 can have a constant inner diameter extending from the mixing chamber to anoutlet opening 436. Thetip 416 can further include one ormore side passages 438, such as two, three, four, or more, configured similar to theside passages 422 of the above form extending at an angle with respect to the longitudinal axis of the catheter. As shown, theside passages 438 can connect to thetransition portion 434 to introduce cerebrospinal fluid to the flow of fluid through thecatheter 400 providing flow mass amplification within the mixingchamber 432. - Another example
atraumatic tip 416 is shown inFIG. 37c that includesside passages 440 and a narrowingchoke 442. In this form, theside passages 440 extend radially through thecatheter 400 and connect to thecentral passage 404 in thechoke 442. Further, the inner diameter of thecentral passage 404 and anoutlet opening 444 can be generally equal. - Another example
atraumatic tip 416 is shown inFIG. 37d . In this form, thedistal outlet 418 can include a reduced-diameter opening 446 relative to the inner diameter of thecentral passage 404. Theopening 446 gives the distal outlet 418 a nozzle effect. - For some applications, it may be desirable to dispense a composition along a length of the
catheter 400 into the intrathecal space of a patient. To achieve this, as shown inFIGS. 38a-38d , thecatheter 400 can include one or moreradial outlets 448 disposed along a length of thecatheter 400 between the proximal anddistal ends FIG. 38a , theradial outlets 448 can be disposed in a spiral configuration extending along a length and around a circumference of thecatheter 400. The spiral configuration of this form ensures that the composition has a maximized exposure and spread within the intrathecal space. - In a second example form, as shown in
FIG. 38b , theradial outlets 448 can be disposed in one ormore rings 450 with theradial outlets 448 distributed about a circumference of thecatheter 400. Therings 450 can be spaced from one another along the axial length of thecatheter 400 and can be disposed within a plane generally normal to the axial length of thecatheter 400. In a third example form, as shown inFIG. 38c , theradial outlets 448 can be disposed in one ormore bands 452 running the axial length of thecatheter 400. Thecatheter 400 can include oneband 452 to distribute fluid in one radial direction, two, three, four, or more, as desired. In another example, as shown inFIG. 38d , theradial outlets 448 can include both one ormore rings 450 and one ormore bands 452. - In some versions, the distal and
radial outlets radial outlets distal outlet 418. In a second example, the distal andradial outlets distal outlet 418 is generally equal to an amount of fluid dispensed through theradial outlets 448. - In order to confirm that the
catheter 400 has been correctly implanted into the intrathecal space and/or is in a fully functioning form, thecatheter 400 may include one or more radiopaque markings or components to be visible under imaging. For example, theentire catheter 400 can be radiopaque or, as shown inFIG. 35a , thecatheter 400 can includeradiopaque markings 454 disposed at featured locations, such as below thedistal end 406, adjacent to a start of theradial outlets 448, adjacent to an end of theradial outlets 448, and so forth. - In some examples, the
catheter 400 can be provided with an extended length so that a clinician can cut thecatheter 400 to a desired length for a particular patient. For example, thecatheter 400 can be provided to the clinician with a length up to 140 cm. Further, thecatheter 400 described herein can be a 3-fr, 1 mm outer diameter catheter. Other suitable outer diameters for thecatheter 400 can be in the range of about 0.25 mm to about 1.5 mm, or in the range of about 0.5 mm to about 1.25 mm, or in the range of about 0.75 mm to about 1.0 mm. - The spinal column of a patient is surrounded by a
dura 458 that can be penetrated by a suitable instrument, such as a Tuohy needle, to create anopening 456 for the insertion of acatheter 400, configured as described above. As shown inFIG. 35b , in order to minimize or prevent tearing of theopening 456 and leakage of cerebrospinal fluid, a clinician can utilize agrommet 460 to abut thedura 458 and extend around theopening 456 therein. Thegrommet 460 can include asleeve portion 462 sized to extend around thecatheter 400 and aflange portion 464 projecting outwardly from thesleeve portion 462 and configured to be placed on thedura 458 over and around theopening 456. - In some versions, the
catheter 400 can further be provided or implanted along with aplug 466 having abody 468 with apassage 470 extending therethrough for reception of thecatheter 400. Thepassage 470 extends through theplug body 468 from adistal end 472 to an opposite,proximal end 474 thereof. As shown, one or both of theends body 468 can have a bent configuration with thedistal end 472 at an angle with respect to theproximal end 474. For example, thebody 468 can include abend 476, that can be generally 90 degrees, e.g., within 5 to 10 degrees, as shown, although other acute or obtuse angles can also be utilized. In order to thread thecatheter 400 through theplug 466, thebody 468 can include anopening 478 that extends through thebody 468 from thepassage 470 to anexterior 480 of theplug 466. A clinician can utilize theopening 478 to manipulate thecatheter 400 through theplug body 468 and out through thedistal end 472. - A
fascia 482 extends around thedura 458 and, as such, thefascia 482 can also be penetrated by the instrument to create anopening 484 therein in addition to theopening 456 in thedura 458. Theplug 466 can advantageously be implanted through theopening 484 in thefascia 482 to create a seal with the tissue of thefascia 482 to minimize or prevent leakage of cerebrospinal fluid. The beveled configuration of thedistal end 472 can also aid a clinician in inserting theplug 466 through thefascia 482. - In one approach, shown in broken lines in
FIG. 35c , theplug 466 can be inserted into thefascia 482 until thedistal end 472 abuts thedura 458. So configured, thedistal end 472 can extend around theopening 456 to minimize or prevent tearing and cerebrospinal fluid leakage. In another approach, shown in solid lines inFIG. 35c , theplug 466 can be inserted into thefascia 482 with thedistal end 472 spaced from thedura 458. In either approach, after theplug 466 is positioned, a clinician can stitch up theopening 484 in thefascia 482 with asuture 486 so that sometissue 488 of thesuture 486 is captured between thesuture 486 and theplug body 468. Thereafter, when the clinician tightens thesuture 486, thetissue 488 is tightly captured between thesuture 486 and theplug body 468 creating a seal preventing or minimizing the leakage of cerebrospinal fluid through thefascia opening 484. In some versions, theplug body 468 can include anannular recess 490 extending therearound, or a plurality of recesses distributed around the circumference, adjacent to thedistal end 472. When thesuture 486 is tightened, thetissue 488 can be drawn into therecess 488 preventing or minimizing subsequent movement of thesuture 486. - As shown, the
body 468 can further include outwardly projectingtabs 492 havingopenings 494 extending therethough. A clinician can utilize thetabs 492 to secure theproximal end 474 of theplug body 468 to thefascia 482 withsutures 492. Advantageously, the bent configuration of thebody 468 allows the plugproximal end 474 to extend along thefascia 482 for a compact configuration after implantation. In one form, theplug 466 can be made of silicone or other suitable material. - In an alternative or additional approach, the
catheter 400 can include a portion with an outwardly tapered configuration where the increased outer diameter is configured to engage theopening 456 in thedura 458 to minimize or prevent tearing. - As briefly described above, the
catheter 400 can be configured to couple to theport delivery opening chamber suitable connection assemblies 500, some or all of which can advantageously be free of metal components. In a first example, shown inFIGS. 2 and 4 , theport cylindrical cavity 502 extending radially through thebody delivery opening interior end 504 and an openexterior end 506. Thecylindrical cavity 502 can include a threadedportion 508 and acounterbore 510 at the openexterior end 506. Next, anannular gasket 512 can be placed over theproximal end 406 of thecatheter 400 and the assembledgasket 512 andcatheter 400 is inserted into thecavity 502 until thegasket 512 andcatheter 400 abut theinterior end 504 thereof. As shown, this aligns thecentral passage 404 of thecatheter 400 with thedelivery opening catheter 400 to theport ferrule 514 extending around thecatheter 400 can be inserted into thecavity 502 to engage the threadedportion 508. As theferrule 514 is threaded into thecavity 502, theferrule 514 engages thegasket 512 and causes thegasket 512 to compress and radially expand to tightly engage the surface of thecavity 502 and thecatheter 400. Thecounterbore 510 can be sized to receive a portion of ahead 516 of theferrule 514 to minimize outwardly protruding features on theport gasket 512 can be a singular component or can be composed of multiple components, as desired. - For ease of installation, the inner diameter of the
gasket 512 can be larger than an outer diameter of thecatheter 400. Further, theproximal end 406 of thecatheter 400 can be reinforced to have a higher hoop strength to withstand the compressive force generated by thegasket 512. If desired, theferrule 514 and/orcavity 502 can include a torque limiting tool to prevent overtightening and the possible resulting damage to thecatheter 400. - In an alternative example, as shown in
FIG. 39 , thecavity 502 can include acatheter counterbore 518 at theinterior end 504 thereof. Thecatheter counterbore 518 has a diameter sized to receive a portion of theproximal end 406 of thecatheter 400 therein, but also sized to be smaller than thegasket 512. With this configuration, the end of thecatheter 400 is not compressed by thegasket 512 during tightening and therefore possible crushing of the end is prevented. - In another example, as shown in
FIG. 40 , theassembly 500 can utilize a snap-fit connection rather than a threaded connection as described above with respect toFIGS. 2, 4, and 39 . Pursuant to this, thecavity 502 can include an annular snap-fit recess 520 having a radiallyoutward stop surface 522 and aferrule 524 can include an outwardly projectingannular prong 526. So configured, theferrule 524, extending around thecatheter 400, can be inserted into thecavity 502 until theprong 526 is biased into therecess 520 by the resiliency of theferrule 524 and/or thecatheter 400. Theprong 526 engages thestop surface 522 of therecess 520, preventing removal of theferrule 524. Further, therecess 520 can be located within thecavity 502 and thegasket 512 can be sized to provide an optimal amount of compression to result in a fluid tight seal without overly compressing thecatheter 400. Although therecess 520 andprong 526 are described as annular, discrete portions that can be aligned during insertion is within the scope of this disclosure. - In another example as shown in
FIG. 41 , theassembly 500 can utilize a luer lock connection rather than a threaded or snap-fit connection as described above. Pursuant to this, thecavity 502 can include a plurality ofradial recesses 528 with outwardly extendingopenings 530. Aferrule 532 of this form can include a plurality ofradial tabs 534 that are positioned to align with theopenings 530. For example, thetabs 534 andopenings 530 can be symmetrically disposed around theferrule 532 andcavity 502 respectively. During assembly, a clinician can align thetabs 534 with theopenings 530, insert theferrule 532 into thecavity 502 until thetabs 534 align with theradial recesses 528, and turn the ferrule 532 a predetermined amount, such as a quarter turn, to lock theferrule 532 to theport tabs 534. Further, the radial recesses 528 can be located within thecavity 502 and thegasket 512 can be sized to provide an optimal amount of compression to result in a fluid tight seal without overly compressing thecatheter 400. - In another example, as shown in
FIG. 42 , theport tube 536 having apassage 538 extending from thedelivery opening chamber tube 536 can have an outer diameter that is equal to or smaller than an inner diameter of the catheterproximal end 406 so that theproximal end 406 can be inserted over and around thetube 536. To secure thecatheter 400 to thetube 536, aspring 540, which can be made of metal, such as nitinol, for example, having a resting state compressing thecatheter 400, can be twisted to loosen thespring 540 to allow the catheterproximal end 406 to be inserted onto thetube 536 and released to compress and secure thecatheter 400 to theport spring 540 to easily loosen the windings thereof during assembly. - In another example, as shown in
FIG. 43 , the outwardly projectingtube 536 can include a backstop 542 extending around an intermediate portion thereof and the catheterproximal end 406 can have a press-fit ring 544 mounted thereto. As shown, the catheterproximal end 406 can have an expanded diameter to secure within thering 544 and aninterior opening 546 of thering 544 can be sized to have a press-fit engagement with thetube 536. So configured, a clinician can simply align theopening 546 with thetube 536 and press thering 544 until thering 544 abuts the backstop 542. - In another example, as shown in
FIG. 44 , theport annular wall 548 encircling thetube 536. Theassembly 500 of this form, can further include an o-ring 550 having an inner diameter smaller than an outer diameter of the catheterproximal end 406 such that the o-ring 550 provides a compressive force on thecatheter 400 when mounted therearound. During assembly, the o-ring 550 can be shifted longitudinally along thecatheter 400 so that theproximal end 406 can be fully inserted between thetube 536 andwall 548. Thereafter, the o-ring 550 can be stretched or rolled onto thewall 548 to provide a compressive force through thewall 548 to thecatheter 400 andtube 536. By one approach, the inner diameter of thewall 548 can be generally equal, within 1 mm, of an outer diameter of thecatheter 400 so that thecatheter 400 is tightly received in the annular space between thewall 548 andtube 536. The o-ring 550 can be formed from rubber or any suitable elastomer, for example. - In another example, as shown in
FIG. 45 , theassembly 500 of this form can utilize a clampingmember 552 to secure the catheterproximal end 406 to thetube 536. The clampingmember 552 can include upper and lower portions 554, 556 that are movable with respect to one another to be clamped around the catheterproximal end 406 and thetube 536 during assembly. As shown, the catheterproximal end 406 and thetube 536 can be axially aligned in a lap joint connection so that the ends thereof abut one another and the clampingmember 552 can be secured thereover to provide a fluid tight seal. The upper and lower portions 554, 556 can be secured together by any suitable mechanism, including snap-fit, crimping, an attachment member, and so forth. - In another example, as shown in
FIG. 46 , theport annular wall 558 encircling thetube 536 creating an annularcatheter reception space 560 between thewall 558 andtube 536. The catheterproximal end 406 of this form can have an enlarged outer diameter as compared to the main body of thecatheter 400, such that theproximal end 406 has greater hoop strength and can withstand greater compressive forces during assembly. Pursuant to this, thereception space 560 can be sized to receive the catheterproximal end 406 therein in a compressive, press-fit configuration to secure thecatheter 400 to theport tube 536 andcatheter 400. - In another example, as shown in
FIG. 47 , theport pre-connected assembly 562 including aflexible tube 564 secured to thebody delivery opening connector 566. Theconnector 566 includes acentral stem 568 and surroundinghousing 570 that define an annularcatheter reception space 572 therebetween. So configured, during assembly a clinician can insert the catheterproximal end 406 into thereception space 572 to fluidly couple thecatheter 400 to theport ring 574 on thehousing 570 in similar configuration as described above with respect toFIG. 43 to provide a compressive force on thecatheter 400 andstem 568. - In another example, as shown in
FIG. 48 , theport connection member 576 having a base 578 and an outwardly projectingstem 580, which can be made of metal, such as titanium, for example, Theconnection member 576 includes apassage 582 therethrough that is fluidly coupled to thedelivery opening stem 580 can includebarbs 583 that extend outwardly from an intermediate portion thereof to engage and retain the catheterproximal end 406 after assembly. Theassembly 500 of this form can further include aplastic housing 584 extending around theconnection member 576 to engage theouter jacket 414 of thecatheter 400. So configured, a clinician can insert the catheterproximal end 406 over thestem 580 until thecatheter 400 abuts thebase 578. Thebarbs 583 andhousing 584 provide a compressive force on thecatheter 400 to secure thecatheter 400 to theport - In another example, as shown in
FIG. 49 , thetube 536 can have an outer diameter that is larger than an inner diameter of thecatheter 400 and the catheterproximal end 406 can be flexible to be stretched over thetube 536 during assembly. By one approach, thetube 536 can include a radial lip orbarb 586 extending therearound to retain the stretchedcatheter end 406 on thetube 536. Given the flexible nature of the catheterproximal end 406 of this form, theassembly 500 can further include a rigid orresilient sleeve 588 that extends along the flexible length of thecatheter 400 to prevent the flexible portion from becoming kinked. - As is understood, implantation of a catheter into the intrathecal space of a patient can be achieved using a stylet. As shown in
FIG. 50 , theport stylet 602 can be pre-loaded and provided with theport radial cavity 604 extending between thechamber body septum 606 received within thecavity 604. In the illustrated form, thecavity 604 includes an outwardly projectingrecess 608 to receive aflange portion 610 of theseptum 606 to prevent or minimize movement of theseptum 606 while thestyle 602 is moved therethrough. The side septum assembly 600 can advantageously be located across thechamber delivery opening stylet 602 can be easily threaded therethrough. Further, the side septum assembly 600 can be utilized with any of thecatheter connection assemblies 500 described above. - One example method for implanting the fluid delivery systems described herein includes selecting a suitable bony structure of a patient for implantation of the
port port distal end 408 of thecatheter 400 in the intrathecal space of a patient, utilizing the features and properties of thecatheter 400 to tunnel theproximal end 406 of thecatheter 400 under the skin within the intrathecal space to the subcutaneously implantedport catheter 400 to theport connection assemblies 500 described herein. - After the
port catheter 400 have been implanted and coupled together, a clinician can utilize the fluid delivery system to sample cerebrospinal fluid for diagnostic purposes or can utilize the system to deliver a composition (e.g., a dose of a therapeutic agent) to the intrathecal space of the patient. The clinician can locate thesubcutaneous port port septum chamber outlets catheter 400 into the intrathecal space of the patient. The medication can be delivered as bolus or per infusion algorithm from the Pulsar pump using the Pulsar auto-injector pump. In some cases where the composition comprises a therapeutic agent, an approved dosing regimen of the therapeutic agent may require removal of cerebrospinal fluid before injection of the therapeutic agent, which can be done manually, using a standard syringe pump, or using Pulsar auto injector pump from theport - The
port chamber port - In another example, as shown in
FIG. 51 , thechamber port more dosages 650 of a therapeutic agent. A clinician can dispense one of thedoses 650 by applying pressure to theseptum port dose 650 through thedelivery opening catheter 400. If more than onedose 650 is provided, thedosages 650 can be separated bymovable doors 652 extending across thechamber doors 652 can be metallic and be selectively and non-invasively moved by a clinician using anexternal device 654 having one or more magnets therein. - The fluid delivery systems described herein can further be provided as a set, which can include an implantation kit/introducer, anchoring components for the
catheter 400, and/or a facial anchor. Further, if desired, a filter can be provided in the catheter,delivery opening chamber - The device described herein is suitable for administering any fluid composition, such as a pharmaceutical composition comprising one or more therapeutic agents, to a subject. Indeed, the device of the disclosure optionally comprises one or more dosages of a therapeutic agent, such as a therapeutic agent suitable for treating (in whole or in part) a disorder, infection, or injury of the central nervous system or spine. Disorders associated with aspects of the central nervous system or spine include, but are not limited to, spinal muscular atrophy, survival motor neuron deficiency, ankylosing spondylitis, spinal tumors, bipolar disorder, encephalitis, depression, epilepsy, Dravet Syndrome, meningitis, multiple sclerosis, myeopathy, Angelman's Syndrome, CNS lymphoma, Leptomeningeal cancer, Friedreich's Ataxia, hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D), cerebral amyloid angiopathy (CAA), amyloid congophilic angiopathy (ACA), and secondary malignant neoplasms (SMN), or neurodegenerative disorders, e.g., Tau protein-related disorders including Alzheimer's disease, Huntington's disease, alpha-synuclei-related disorders including Parkinson's disease, amyotrophic lateral sclerosis (ALS) including superoxide dismutase 1-related ALS, progressive spranuclear palsy, frontotemporal dementia, and Tourette's syndrome. Infections of the CNS include, but are not limited to, viral meningitis, fungal meningitis, epidural infection, viral encephalitis, and neurosyphilis.
- Any therapeutic agent may be used in the context of the disclosure. Exemplary therapeutic agents include, e.g., nucleic acids, protein therapeutics, cell therapies, and small molecule therapeutics. Examples of protein therapeutics include antibody-based therapeutics, such as antibodies, antibody fragments, or antibody-like protein products that include binding regions of antibodies (e.g., scFv, diabodies, antibody mimetics, and the like). The antibody-based therapeutic may target, e.g., amyloid plaques, tau proteins, cancer antigens, or abnormal alpha-synuclein. Examples of protein therapeutics also include, but are not limited to, hormones, enzymes (e.g., lysosomal enzymes, such as alpha-L-iduronidase, N-acetylgalactosamine-4-sulfatase, or beta-glucuronidase), growth factors (e.g., fibroblast growth factor (FGF) or neurotrophins or neurotrophic factors, such as glial cell-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), or nerve growth factor (NGF)), blood factors, bone morphogenetic proteins, interferons, interleukins, and thrombolytics. Examples of cell-based therapies include, but are not limited to, stem cell therapeutics and immune cells (including modified immune cells, such as CAR T cells). Suitable small molecule therapeutics include, but are not limited to, analgesics, ion channel blockers, anti-convulsive agents, antibiotics or antiviral agents, anti-inflammatories, anticoagulants, chemotherapeutic, anti-depressants, anti-anxiety agents, steroids, and the like. In various aspects, the therapeutic agent is baclofen, morphine, bupivacaine hydrochloride, clonidine hydrochloride, gabapentin, idursulfase, cytarabine, methotrexate, a corticosteroid, edavarone-conjugate, conotoxin, abomorphine, prednisolone hemisuccinate sodium, carbidopa/levodopa, tetrabenazine, benzodiazepines, such as diazepam and midazolam, alphaxalone or other derivative, cyclophosphamide, idursulfase (Elaprase®), iduronidase (Aldurazyme®), topotecan, buslfan, opmaveloxolone, epicatechin, methylprednisolone, frataxin replacement, reservatrol, nicontinamide, AT-010 (RNA that induces splicing modulation in the mature amyloid precursor protein mRNA), Cerebril™, an anti-Aβ antibody, elenbecestat, a corticosteroid, or nusinersen (Spinraza®), or combinations thereof.
- In various aspects, the therapeutic agent is a nucleic acid, including DNA or RNA, which may be single stranded or double stranded and which may be modified or unmodified. Suitable nucleic acid-based therapeutic agents include, but are not limited to, antisense oligonucleotides, ribozymes, miRNA, siRNA, and shRNA. Optionally, the nucleic acid targets a gene selected from the group consisting of APP, MAPT, SOD1, BACE1, CASP3, TGM2, TARDBP, ADRB1, CAMK2A, CBLN1, CDK5R1, GABRA1, MAPK10, NOS1, NPTX2, NRGN, NTS, PDCD2, PDE4D, PENK, SYT1, TTR, FUS, LRDD, CYBA, ATF3, CASP2, HRK, C1QBP, BNIP3, MAPK8, MAPK14, Rac1, GSK3B, P2RX7, TRPM2, PARG, CD38, STEAP4, BMP2, GJA1, TYROBP, CTGF, ANXA2, DUOX1, RTP801, RTP801L, NOX4, NOX1, NOX2 (gp91pho, CYBB), NOX5, DUOX2, NOXO1, NOXO2 (p47phox, NCF1), NOXA1, NOXA2 (p67phox, NCF2), p53 (TP53), HTRA2, KEAP1, SHC1, ZNHIT1, LGALS3, SESN2, SOX9, ASPP1, CTSD, CAPNS1, FAS, FASLG, CAPN1, FADD, CASP1, CASP9, p75NTR, PARK2, HTT (with expanded repeats), NogoA, MAG, OMGP, NgR1, PDE4, BCAN, NCAN, PTPRZ1, TNC, NRP1, NRP2, PLXNA1, PLXNA2, PLXNB1, PLXNC1, TROY, LRRC1, ROCK1, LimK1, LimK2, CFL1, KCNC4, KCNE3, NAT8L, FKBP1A, FKBP4, LRRK2, DYRK1A, AKAP13, UBE2K, WDR33, MYCBP2, SEPHS1, HMGB1, HMGB2, TRPM7, BECN1, THEM4, SLC4A7, MMP9, SLC11A2, ATXN3, ATXN1, ATXN7, PRNP, EFNB3, EPHA4, EFNAS, EPHA7 and EFNB2, such that gene expression or function is modified.
- In some embodiments, the therapeutic agent is an oligonucleotide comprising at least one modified nucleotide, optionally a modified nucleotide that reduces binding to cerebral spinal fluid (CSF) proteins. In various embodiments, the modified nucleotide includes a substituent at the 2′-position, such as a 2′-O-2-methoxyethyl (“2′-MOE”) group, as shown below, wherein X is O or S.
- Oligonucleotides comprising a 2′-MOE modification can distribute rapidly in central nervous system tissues. Oligonucleotides comprising such modifications exhibit extended half-lives in CSF and central nervous system tissues, which can result in less frequent dose administration.
- In some cases, the modified nucleotide can include a 2,4-constrained group, such as a constrained 2-O-ethyl (“cEt”) group. In various cases, the cEt group can have S-stereochemistry (“S-cEt”), as shown below, wherein X is 0 or S.
- Nucleic acids modified with a constrained ethyl group, such as S-cEt, can exhibit enhanced thermal stability, good potency, and a good therapeutic profile.
- Optionally, the nucleic acid encodes a beneficial protein that, e.g., replaces an absent or defective protein, or encodes a cytotoxic protein that achieves a therapeutic effect, such as cancer cell death. Any of the protein-based therapeutics described herein may be delivered to a subject via delivery of a nucleic acid encoding the protein under conditions which allow expression in vivo. For example, in various embodiments, the nucleic acid encodes a neurotrophic factor such as, but not limited to, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5), neurotrophin-6 (NT-6), ciliary neurotrophic factor (CNTF), glial cell line-derived neurotrophic factor (GDNF), the fibroblast growth factor family (e.g., FGF 1-15), leukemia inhibitory factor (LIF), certain members of the insulin-like growth factor family (e.g., IGF-1), a neurturin, persephin, a bone morphogenic protein (BMPs), an immunophilin, a member of the transforming growth factor (TGF) family of growth factors, a neuregulin, epidermal growth factor (EGF), platelet-derived growth factor (PDGF), vascular endothelial growth factor family (e.g. VEGF 165), follistatin, or Hifl, or combinations thereof.
- In various aspects, the nucleic acid is present in a viral vector. Any viral vector appropriate for delivering a therapeutic agent to a human subject may be used. Examples of viral vectors include, e.g., herpes simplex virus (HSV) vectors, adenovirus (Ad) vectors, parvoviral-based vectors (e.g., adeno-associated viral vectors), chimeric Ad-AAV vectors, and retroviral vectors (including lentiviral vectors, HIV vectors). Any of these gene transfer vectors can be prepared using standard recombinant DNA techniques described in, e.g., Sambrook et al., Molecular Cloning, a Laboratory Manual, 2d edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1989), and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and John Wiley & Sons, New York, N.Y. (1994).
- In some embodiments, the viral vector is an AAV vector. AAV vectors used for administration of a therapeutic nucleic acid typically have approximately 96% of the parental genome deleted, such that only the terminal repeats (ITRs), which contain recognition signals for DNA replication and packaging, remain. Delivering the AAV rep protein enables integration of the AAV vector comprising AAV ITRs into a specific region of genome, if desired. AAV vectors are useful for delivering payload to the central nervous system due, at least in part, to their safety profile, long-term gene expression, and ability to infect both dividing and quiescent cells, including neurons. Multiple serotypes of AAV exist and offer varied tissue tropism. Known serotypes include, for example, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10 and AAV11. AAV vectors may be engineered to alter the virus native tropism or improve infection by modifying the viral capsid or packaging the genome of one serotype into the capsid of a different serotype. AAV vectors have been used to deliver a number of transgenes to treat a variety of diseases, including ASP to treat Canavan disease; CLN2 to treat Late infantile neuronal ceroid lipofuscinosis; SGSH to treat mucopolysaccharidosis IIIA; NAGLU to treat mucopolysaccharidosis IIIB; ARSA to treat metachromatic leukodystrophy; GAD, AADC, NTN, GDNF, AADC to treat Parkinson®; and NGF to treat Alzheimer®. See, e.g., Hocquemiller et al., Hum Gene Ther., 27(7), 478-496 (2016), hereby incorporated by reference. The genomic sequences of AAV, as well as the sequences of the ITRs, Rep proteins, and capsid subunits are known in the art. See, e.g., International Patent Publications Nos. WO 00/28061, WO 99/61601, WO 98/11244; as well as U.S. Pat. No. 6,156,303, Srivistava et al. (1983) J Virol. 45:555; Chiorini et al (1998) J Virol. 71:6823; Xiao et al (1999) J Virol. 73:3994; Shade et al (1986) J Virol. 58:921; and Gao et al (2002) Proc. Nat. Acad. Sci. USA 99:11854.
- In various embodiments, the device is used to deliver one or more gene editing agents to a subject, such as the clustered regularly interspaced short palindromic repeats (CRISPR) associated protein (Cas) system. CRISPR-Cas and similar gene targeting systems are in the art with reagents and protocols readily available. See, e.g., Maliet al., Science, 339(6121), 823-826 (2013); and Hsu et al., Cell, 157.6: 1262-1278 (2014). Exemplary genome editing protocols are described in Doudna and Mali, “CRISPR-Cas: A Laboratory Manual” (2016) (CSHL Press, ISBN: 978-1-621821-30-4) and Ran et al., Nature Protocols 8(11): 2281-2308 (2013). The CRISPR/Cas system comprises a CRIPSR/Cas nuclease (typically Cas9) and guide RNA (or crRNA-tracrRNA) comprising a short nucleotide targeting sequence that directs the nuclease to a genome location of interest. The guide RNA(s) and coding sequence for the Cas nuclease, optionally packaged into viral vectors, can be delivered to the CSF via the device of the disclosure. The CRISPR/Cas system is further described in, e.g., U.S. Patent Publication Nos. 2018/0223311.
- In various aspects, the disclosure provides a method of treating Huntington's disease, Spinal Muscular Atrophy (SMA), survival motor neuron (SMN) deficiency, amyotrophic lateral sclerosis (ALS) (including superoxide dismutase 1 (SOD1)-related ALS), Angelman's syndrome, Dravet syndrome, Alzheimer's disease and other tau protein-related disorders, progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), alpha-synuclei-related disorders including Parkinson's Disease, central nervous system (CNS) lymphoma, leptomeningeal cancer, Friedreich's Ataxia, hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D), cerebral amyloid angiopathy (CAA), amyloid congophilic angiopathy (ACA), or secondary malignant neoplasms (SMN). The method comprises implanting a fluid delivery system in the patient such that a catheter of the fluid delivery system is disposed within the patient's intrathecal space, the catheter characterized by a catheter body having an outer diameter in the range of about 0.25 mm to 1.5 mm and a composite, kink-resistant structure. The fluid delivery system further comprises a grommet having a sleeve portion extending around the catheter body and a flange portion to engage the dura of the patient over a catheter opening therein. The method further comprises releasing a therapeutic agent (such as any one or more of the therapeutic agents described above) via the catheter into the intrathecal space, such that the disorder is treated.
- It will be appreciated that elements in the figures are illustrated for simplicity and clarity and have not necessarily been drawn to scale. For example, the dimensions and/or relative positioning of some of the elements in the figures may be exaggerated relative to other elements to help to improve understanding of various embodiments of the present invention. Also, common but well-understood elements that are useful or necessary in a commercially feasible embodiment are often not depicted in order to facilitate a less obstructed view of these various embodiments. The same reference numbers may be used to describe like or similar parts. Further, while several examples have been disclosed herein, any features from any examples may be combined with or replaced by other features from other examples. Moreover, while several examples have been disclosed herein, changes may be made to the disclosed examples within departing from the scope of the claims.
- Those skilled in the art will recognize that a wide variety of modifications, alterations, and combinations can be made with respect to the above described embodiments without departing from the scope of the invention, and that such modifications, alterations, and combinations are to be viewed as being within the ambit of the inventive concept.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/172,817 US20210162173A1 (en) | 2018-08-27 | 2021-02-10 | Fluid delivery systems and methods |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/113,955 US10940290B2 (en) | 2018-08-27 | 2018-08-27 | Fluid delivery systems and methods |
US17/172,817 US20210162173A1 (en) | 2018-08-27 | 2021-02-10 | Fluid delivery systems and methods |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/113,955 Continuation US10940290B2 (en) | 2018-08-27 | 2018-08-27 | Fluid delivery systems and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210162173A1 true US20210162173A1 (en) | 2021-06-03 |
Family
ID=69587034
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/113,955 Active US10940290B2 (en) | 2018-08-27 | 2018-08-27 | Fluid delivery systems and methods |
US17/172,817 Pending US20210162173A1 (en) | 2018-08-27 | 2021-02-10 | Fluid delivery systems and methods |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/113,955 Active US10940290B2 (en) | 2018-08-27 | 2018-08-27 | Fluid delivery systems and methods |
Country Status (1)
Country | Link |
---|---|
US (2) | US10940290B2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3524195A4 (en) * | 2016-10-06 | 2020-05-06 | Kitazato Corporation | Living cell transplanting tool |
US11396417B2 (en) * | 2019-07-30 | 2022-07-26 | Voyager Products Inc. | System and method for dispensing liquids |
US20220316469A1 (en) * | 2019-07-30 | 2022-10-06 | Voyager Products Inc. | System and method for dispensing liquids |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5676659A (en) * | 1993-11-12 | 1997-10-14 | Medtronic, Inc. | Small diameter, high torque catheter |
US20060264898A1 (en) * | 2005-04-27 | 2006-11-23 | Beasley Jim C | Infusion apparatuses and related methods |
US20070078391A1 (en) * | 2005-09-30 | 2007-04-05 | Angiodynamics Inc. | Implantable medical device |
US20080114308A1 (en) * | 2006-11-13 | 2008-05-15 | Di Palma Giorgio | Vascular Access Port with Catheter Connector |
US20120022502A1 (en) * | 2008-04-22 | 2012-01-26 | Becton, Dickinson And Company | Systems and methods for improving catheter hole array efficiency |
US20150025478A1 (en) * | 2005-04-27 | 2015-01-22 | C. R. Bard, Inc. | Reinforced Septum for an Implantable Medical Device |
US9433764B2 (en) * | 2014-04-18 | 2016-09-06 | Alcyone Lifesciences, Inc. | Systems and methods for shunting fluid |
US20190329015A1 (en) * | 2017-03-07 | 2019-10-31 | Medi Tulip Co., Ltd. | Subcutaneous vein access port and medicine injection device having the same |
US20200306366A1 (en) * | 2017-08-07 | 2020-10-01 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
US20210268251A1 (en) * | 2018-07-13 | 2021-09-02 | Bard Peripheral Vascular, Inc. | Implantable Ports, Implantable Port-Detecting Devices, and Methods Thereof |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4557721A (en) * | 1983-11-29 | 1985-12-10 | Cordis Corporation | Servo valve |
US4929236A (en) | 1988-05-26 | 1990-05-29 | Shiley Infusaid, Inc. | Snap-lock fitting catheter for an implantable device |
US5185003A (en) | 1989-04-11 | 1993-02-09 | B. Braun Melsungen Ag | Port for injecting medicaments |
AU4242996A (en) * | 1994-11-23 | 1996-06-17 | Navarre Biomedical, Ltd. | Flexible catheter |
US5954687A (en) | 1995-04-28 | 1999-09-21 | Medtronic, Inc. | Burr hole ring with catheter for use as an injection port |
US7131962B1 (en) | 1996-06-12 | 2006-11-07 | Nd Partners Llc | Port device for subcutaneous access to the vascular system of a patient |
US6193685B1 (en) * | 1996-11-26 | 2001-02-27 | Schneider (Usa) Inc. | Perfusion catheter |
US6039712A (en) | 1997-11-04 | 2000-03-21 | Terence M. Fogarty | Implantable injection port |
GB9928248D0 (en) | 1999-12-01 | 2000-01-26 | Gill Steven S | An implantable guide tube for neurosurgery |
US6962580B2 (en) | 2002-09-17 | 2005-11-08 | Transoma Medical, Inc. | Vascular access port with needle detector |
US20050137579A1 (en) * | 2003-12-23 | 2005-06-23 | Medtronic, Inc. | Permeable membrane catheters, systems, and methods |
US8267905B2 (en) | 2006-05-01 | 2012-09-18 | Neurosystec Corporation | Apparatus and method for delivery of therapeutic and other types of agents |
GB0623395D0 (en) * | 2006-11-23 | 2007-01-03 | Renishaw Plc | Port |
US20080275401A1 (en) * | 2007-05-01 | 2008-11-06 | Sage Shahn S | Catheter anchor and system/method regarding same |
CN101678199B (en) | 2007-06-22 | 2013-10-30 | 医疗器械公司 | Low profile venous access port assembly |
US8932271B2 (en) | 2008-11-13 | 2015-01-13 | C. R. Bard, Inc. | Implantable medical devices including septum-based indicators |
US8483845B2 (en) * | 2011-03-11 | 2013-07-09 | Greatbatch Ltd. | Anchor for implantable medical device |
US20130035660A1 (en) * | 2011-08-01 | 2013-02-07 | Alcyone Lifesciences, Inc. | Multidirectional microfluidic drug delivery devices with conformable balloons |
CN104582610B (en) * | 2012-07-24 | 2018-03-20 | 瑞尼斯豪公司 | Neurosurgery apparatus and method |
AR096203A1 (en) * | 2013-05-06 | 2015-12-16 | Alnylam Pharmaceuticals Inc | DOSAGES AND METHODS FOR MANAGING NUCLEIC ACID MOLECULES FORMULATED IN LIPIDS |
WO2016183123A1 (en) | 2015-05-11 | 2016-11-17 | Alcyone Lifesciences, Inc. | Drug delivery systems and methods |
US10123969B2 (en) * | 2015-10-15 | 2018-11-13 | Wisconsin Alumni Research Foundation | Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid |
JP2019521809A (en) | 2016-07-29 | 2019-08-08 | アルキオーネ・ライフサイエンシズ・インコーポレイテッドAlcyone Lifesciences, Inc. | Automatic drug delivery system and method |
WO2018119179A1 (en) | 2016-12-21 | 2018-06-28 | Alcyone Lifesciences, Inc. | Drug delivery systems and methods |
US20180214680A1 (en) | 2017-02-01 | 2018-08-02 | Pfm Medical, Inc. | Identification system for injectable access ports |
US20180214679A1 (en) | 2017-02-01 | 2018-08-02 | Pfm Medical, Inc. | Identification system for injectable access ports |
-
2018
- 2018-08-27 US US16/113,955 patent/US10940290B2/en active Active
-
2021
- 2021-02-10 US US17/172,817 patent/US20210162173A1/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5676659A (en) * | 1993-11-12 | 1997-10-14 | Medtronic, Inc. | Small diameter, high torque catheter |
US20060264898A1 (en) * | 2005-04-27 | 2006-11-23 | Beasley Jim C | Infusion apparatuses and related methods |
US20150025478A1 (en) * | 2005-04-27 | 2015-01-22 | C. R. Bard, Inc. | Reinforced Septum for an Implantable Medical Device |
US20070078391A1 (en) * | 2005-09-30 | 2007-04-05 | Angiodynamics Inc. | Implantable medical device |
US20080114308A1 (en) * | 2006-11-13 | 2008-05-15 | Di Palma Giorgio | Vascular Access Port with Catheter Connector |
US20120022502A1 (en) * | 2008-04-22 | 2012-01-26 | Becton, Dickinson And Company | Systems and methods for improving catheter hole array efficiency |
US9433764B2 (en) * | 2014-04-18 | 2016-09-06 | Alcyone Lifesciences, Inc. | Systems and methods for shunting fluid |
US20190329015A1 (en) * | 2017-03-07 | 2019-10-31 | Medi Tulip Co., Ltd. | Subcutaneous vein access port and medicine injection device having the same |
US20200306366A1 (en) * | 2017-08-07 | 2020-10-01 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
US20210268251A1 (en) * | 2018-07-13 | 2021-09-02 | Bard Peripheral Vascular, Inc. | Implantable Ports, Implantable Port-Detecting Devices, and Methods Thereof |
Also Published As
Publication number | Publication date |
---|---|
US20200061337A1 (en) | 2020-02-27 |
US10940290B2 (en) | 2021-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200061362A1 (en) | Fluid delivery systems and methods | |
US20210162173A1 (en) | Fluid delivery systems and methods | |
US11850374B2 (en) | Therapy specific, pre-programmed auto injection device | |
ES2647789T3 (en) | Injection device for minimally invasive procedures | |
CN112867529B (en) | Fluid delivery systems and methods | |
AU2009202335B2 (en) | Pulsatile flux drug delivery | |
KR102583350B1 (en) | Electroporation device for the eye with a support and with a needle electrode | |
US20190255284A1 (en) | Fluid Delivery Systems and Methods | |
CN112204140A (en) | Biological diffusion chamber | |
WO2004110533A1 (en) | Needleless syringe having medical agent accommodated therein | |
US10973500B2 (en) | Device and method for aspirating bone marrow | |
US20210016000A1 (en) | Image-guided lumbar puncture aspiration and injector system and method | |
US20190314574A1 (en) | Devices and methods for percutaneous lung intratumoral therapy delivery | |
US20220370716A1 (en) | Fluid delivery systems and methods of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: ALCYONE LIFESCIENCES, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SINGH, DEEP ARJUN;FREUND, JONATHAN;ANAND, PJ;AND OTHERS;REEL/FRAME:058169/0432 Effective date: 20181105 |
|
AS | Assignment |
Owner name: ALCYONE THERAPEUTICS, INC., MASSACHUSETTS Free format text: CHANGE OF NAME;ASSIGNOR:ALCYONE LIFESCIENCES, INC.;REEL/FRAME:058734/0707 Effective date: 20201125 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |